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Summary 
 
Introduction and purposes.  
Multiple myeloma (MM) is an incurable malignancy of mature plasma cells (PCs), and its pathogenesis 
is only partially understood. Recently, whole exome sequencing studies have identified mutations of 
DIS3, a catalytic subunit of the human exosome complex, in about 10% of MM patients. This study was 
aimed at investigating the spectrum of DIS3 mutations indifferent stages of plasma cell dyscrasia. 
 
Experimental design.  
To analyze DIS3 mutations, we investigated by next generation sequencing (NGS) a retrospective 
cohort of 130 cases with MM at onset and 17 at relapse (of whom 15 were also tested at onset). 
Moreover, we examined 24 patients with primary PC leukemia (pPCL), 12 with secondary PCL and 20 
multiple myeloma cell lines. Deep sequencing of the PIN (exons 1-4) and RNB (exons 10-18) DIS3 
functional domains was performed by Roche 454 pyrosequencing on the Genome Sequencer Junior 
instrument. Mutations were validated by conventional Sanger sequencing or independent ultra-deep 
454 pyrosequencing. All samples were characterized by fluorescence in situ hybridization (FISH) for 
the main genomic aberrations, such as IGH translocations, 13q and 17p deletions, hyperdiploidy, 1p33 
(CDKN2C) loss and 1q21.3 (CKS1B) gain. In order to verify if the mutations detected on genomic DNA 
were expressed at transcriptomic level, DIS3 cDNA of mutated cases was subjected to deep 
sequencing. Global gene expression of MM patients was also profiled, looking for transcriptional 
patterns possibly related to DIS3 mutations. Additionally, to investigate DIS3 mutation status 
longitudinally, we analyzed 20 patients whose bone marrow specimens were collected at two different 
time points. Finally, the association of DIS3 mutations with clinical outcome was tested, comparing 
wild-type patients (n=12) with those characterized by mutations in PIN or RNB functional domains of 
DIS3 (n=4). 
 
Results. 
NGS analysis revealed the presence of 41 coding non-synonymous variants, with a mutant allele 
frequency ranging from 0.38% to 100% of total reads (median depth of coverage 245x, range: 64-
1160). Among the 41 tumor-specific mutations, 30 (73%) were single nucleotide variations, and the 
remaining 11 (27%) were indels. Nine of these variants have been already reported by others, eight of 
which also specifically in MM patients, while 32 were novel. The great majority of mutations identified 
in our cohort of patients affected the RNB domain (30/41, 73.2%). The mutations affected 26 MM 
patients at diagnosis (26/130, 20%), four at relapse (4/17, 23.5%), six pPCL (6/24, 25%), four sPCL 
(4/12, 33.3%) cases, and three multiple myeloma cell lines (3/20, 15%). We observed a positive 
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association of DIS3 mutations with the occurrence of translocations involving IGH@ locus, particularly 
with the t(11;14), and a negative association with hyperdiploid cases, but no association with 13q and 
17p deletion, gain of chromosome 1q and loss of chromosome 1p. Additionally, we showed that 
mutant allele frequencies detected on genomic DNA and on retrotranscribed total RNA are linearly 
correlated. Moreover, in serially analyzed patients, we detected mutations at constant allele frequency 
at both time points, or acquired/increased variants in the late sample, consistent with the expected 
positive selection of mutated subclones. Furthermore, global gene expression profiling analysis 
revealed 119 differentially expressed genes (all up-regulated in mutated cases) between DIS3 mutated 
and wild-type cases. Finally, we tested the association of DIS3 mutations with clinical outcome in 16 
pPCL patients for whom the follow-up was available, showing that mutational events did not show any 
impact neither on PFS nor OS. 
 
 
Conclusion. 
Our data confirm DIS3 as frequently mutated in MM, and importantly, seem to indicate an even greater 
involvement of DIS3 alteration in more advanced stages of PC dyscrasias. Furthermore, these data, 
although requiring confirmation in independent patients’ series, support the hypothesis that DIS3 may 
play a role in development and progression of MM. 
Further studies are required to elucidate the role of this gene in the pathogenesis of MM, as well as its 
potential use as a drug target. 
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Introduction 
MULTIPLE MYELOMA 
 
Multiple myeloma is a malignant disease characterized by proliferation of clonal plasma cells (PC) in 
the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins  
detectable in serum and/or urine and the presence of lytic bone lesions 1. MM accounts for about 10% 
of all hematological cancers 2;3, and the median age at diagnosis is 69 years, with three-quarters of 
patients being diagnosed above the age of 55 years and two of three patients being men. Multiple 
myeloma is the second most frequent haematological malignancy with an age-adjusted incidence of six 
per 100 000 per year in the USA and Europe 4. MM is incurable disease, but with the advent of more 
effective therapeutic strategies and improvements in supportive care, the median survival has 
increased from 3 years to 6 years in the past two decades 5. 
 
Cellular origin of myeloma cells  
Multiple myeloma cells are similar to long-lived, post-germinal centre plasma cells with extensive 
somatic hypermutation of immunoglobulin genes. PCs are characterized by strong bone marrow 
dependence for survival and growth. The immunophenotype of MM cells resembles that of normal, 
terminally differentiated, long-lived BM PC (CD19–CD20–CD45–CD138+). In contrast to normal long-
lived PCs, MM tumors retain some potential for an extremely low rate of proliferation, usually with no 
more than a few per cent of cycling cells, until advanced stages of MM 6. 
 
Pathogenesis 
MM affects antibody‐secreting bone marrow (BM) plasma cells (PCs) and shows a wide clinical  
presentation ranging from the presumed pre-malignant condition of monoclonal gammopathy of 
undetermined significance (MGUS) to smoldering MM, truly overt and symptomatic MM, and extra-
medullary myeloma or plasma cell leukemia (PCL). To date, MM diagnosis is based on the criteria 
established by the International Myeloma Working Group in 2003 7 subsequently updated in 2009 8. 
Osteolytic bone lesions and/or compression fractures detected on routine radiographs, magnetic 
resonance imaging (MRI), or computed tomographic (CT) scans are the most characteristic markers of 
end-organ damage in myeloma. Anemia (occurring in 70% of patients), renal failure (50%), and 
hypercalcemia (25%) are the other established markers of end-organ damage. The presence of one or 
more of these four markers that is felt to be related to the underlying plasma cell disorder is required 
for the diagnosis of the disease (Table 1) 9. 
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Disorder Disease definition 
Monoclonal Gammopathy 
of Undetermined Significance 
(MGUS) 
 Serum monoclonal protein < 3 g/dL 
 Bone-marrow plasma cells <10% 
 Absence of end-organ damage such as lytic bone lesions, 
anemia, hypercalcemia, or renal failure 
Smoldering Multiple Myeloma (SMM; 
asymptomatic multiple myeloma) 
 Serum monoclonal protein (IgG or IgA) ≥3 g/dL and/or 
 Bone-marrow plasma cell ≥10% 
 Absence of end-organ damage such as lytic bone lesions, 
anemia, hypercalcemia, or renal failure 
Multiple Myeloma (MM)  Bone marrow plasma cells ≥10% 
 Presence of serum and/or urinary monoclonal protein 
(except in patients with true non-secretory multiple 
myeloma) 
 Evidence of lytic bone lesions, anemia, hypercalcemia, or 
renal failure 
Table 1. Mayo Clinic diagnostic criteria for selected clonal plasma cell disorders. 
 
Role of the microenvironment in MM 
Similar to long-lived PCs, MGUS and MM cells are dependent on the BM microenvironment: 
interactions between myeloma cells and bone marrow cells or extracellular matrix proteins that are 
mediated through cell-surface receptors (e.g., integrins, cadherins, selectins, and cell-adhesion 
molecules) increase tumor growth, survival, migration, and drug resistance. The adhesion of myeloma 
cells to hematopoietic and stromal cells induces the secretion of cytokines and growth factors, 
including interleukin-6, vascular endothelial growth factor (VEGF), insulin-like growth factor 1, 
members of the superfamily of tumor necrosis factor, transforming growth factor β1, and interleukin-
10. These cytokines and growth factors are produced and secreted by cells in the bone marrow 
microenvironment, including myeloma cells, and regulated by autocrine and paracrine loops 10. The 
adhesion of myeloma cells to extracellular matrix proteins (e.g., collagen, fibronectin, laminin, and 
vitronectin) triggers the up-regulation of cell-cycle regulatory proteins and anti-apoptotic proteins 11. 
Bone lesions are caused by an imbalance in the function of osteoblasts and osteoclasts 12. The 
induction of proangiogenic molecules (e.g., VEGF) enhances the microvascular density of bone marrow 
and accounts for the abnormal structure of myeloma tumor vessels 11. (Figure 1). 
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Figure 1. Interaction between plasma cells and bone marrow in multiple 
myeloma 13 
 
Multi-step clinical course of multiple myeloma 
Virtually every case of MM is preceded by a pre-malignant PC tumor called monoclonal gammopathy 
of undetermined significance (MGUS) 14;15 that, like MM, produces a typical M-spike (almost always 
non-IgM) by serum protein electrophoresis (SPEP) or free light chain in the urine. PC MGUS is age 
dependent, is present in about 4% of individuals over the age of 50, and can progress to MM at average 
rates of 1% per year 16;17. MGUS is distinguished from MM by having a M-spike of <30 g/L, with no 
more than 10 % of BM mononuclear cells being tumor cells, and no end organ damage or other 
symptoms. Progression of MGUS to smoldering MM and symptomatic MM is associated with an 
expanding BM tumor mass and increasingly severe organ impairment or symptoms 15. Despite the 
recent advances in the understanding of the MM pathogenesis, it is still largely impossible to predict 
which MGUS patient will and which one will never progress to MM. Although MM cells are 
characterized by a strong dependence on the BM tumor microenvironment, at late stages of the 
disease the more aggressive tumor may sometimes extend to extramedullary locations, such as spleen, 
liver, and extra-cellular spaces. Extramedullary MM (EMM) can also present with a leukemic phase, 
that is classified as secondary or primary plasma cell leukemia (PCL), depending on whether or not a 
preceding intramedullary MM was recognized. Most of the available human MM cell lines (HMCLs) 
have been generated from EMM or PCL tumors and represent a renewable repository of the oncogenic 
events involved in initiation and progression of the most aggressive end-stage MM tumors 18;19 (Figure 
2). 
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Figure 2. Multi-step molecular pathogenesis of MM. Progression through the different stages of 
multiple myeloma. 
 
Clonal evolution of multiple myeloma 
 
The recent acquisitions based on sequencing data 20-22 suggest that MM is genomically even more 
complex: it is now clear that the process of transformation is not due to a single genetic change but, at 
the time of diagnosis, there are frequently multiple independent clones whose dominance alternates 
during the subsequent phases of the disease in a treatment-related manner. This knowledge has also 
changed the view on the progression of MM from the premalignant condition of MGUS to the final 
stages of plasma cell leukemia. 
Recent studies suggest that greater tumorigenicity and susceptibility to relapse rely on a ‘reserve’ of a 
number of clones, and demand for more detailed studies of the effects of different therapies. This is 
particularly important also in light of emerging evidence that a branching clonal evolution is probably 
a common characteristic of various solid 23;24 and hematological tumors (such as acute myeloid 
leukemia) 25. 
Next generation sequencing analyses of paired samples that have undergone transformation from 
high-risk smoldering MM to overt MM have defined a number of genetic hits that contribute to 
subclonal growth and a survival advantage, and this (together with evidence that the complexity of the 
genome increases with disease stage) has suggested that disease progression is mediated by the 
competition of different subclones, the fittest of which emerges  26.  
Nonetheless, combined whole exome sequencing (WES) and single-cell genetic analysis allowed to 
suggest that MM at onset may present up to six different major malignant clones, which are related by 
either linear or branching evolution (Figure 3). Interestingly, the study of Melchor et al. 27 provided 
evidence that the activation of the RAS/MAPK pathway could be the result of a convergent phenotype 
and be explained as a form of parallel evolution that leads independent clones, originating from a 
common ancestor, to acquire activating mutations in the same pathway or in genes included in the 
same pathway 27. 
The fine characterization of subclones allowed by NGS may also provide important insights into the 
impact of therapy on MM. In the ‘Darwinian’ model of intraclonal heterogeneity, multiple clones 
descend from the same progenitor, each of which has the same main feature but also harbors a set of 
uniquely acquired mutations: the prevalence of specific clones (‘clonal tiding’) over the others depends 
on the selective pressure determined by the microenvironment (the BM niche) or the treatment. This 
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hypothesis further supports the idea that the impact of MM therapy is also related to the underlying 
biology of the disease, and may also explain why high-risk patients have significantly shorter 
progression-free and overall survival than low-risk patients despite their identical response rates 28;29. 
 
 
Figure 3. Clonal composition of multiple myeloma during disease progression and therapy 30. 
 
Genetic architecture and disease progression 
At the cytogenetic level, MM genome is complex and more reminiscent of epithelial cancers than of 
more simple leukemias 28. Many of the genetic lesions that lead to MM have been defined, and can be 
categorized as inherited variation, translocations, copy number abnormalities, mutations, methylation 
and miRNA abnormalities (Table 2). 
 
Chromosomal translocations 
Translocations involving the immunoglobulin heavy chain (IgH) locus are present in at least half of 
MM cases and are thought to result from errors during the physiological process of class-switch 
recombination (CSR) or somatic hypermutation. It is presumed that these translocations represent 
primary – perhaps initiating – oncogenic events as normal B-cells pass through GCs. These 
translocations result in dysregulated expression of an oncogene (such as cyclin D1 (CCND1), CCND3, 
fibroblast growth factor receptor 3 (FGFR3), multiple myeloma SET domain (MMSET; also known as 
WHSC1), MAF and MAFB) that is juxtaposed to the strong Ig enhancers 31.  
It is thought that cyclin D translocations only dysregulate expression of a cyclin D gene. By contrast 
MAF translocations dysregulate expression of a MAF transcription factor that causes increased 
expression of many genes, including cyclin D2 and adhesion molecules that are thought to enhance the 
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Primary genetic events (% of tumors) Secondary genetic events (% of tumors) 
IGH@ translocations and genes affected Gains 
• t(4;14): FGFR3 and MMSET (11%) • 1q: CKS1B and ANP32E (40%) 
• t(6;14): CCND3 (< 1%) • 12p: LTBR 
• t(11;14): CCND1 (14%) • 17q: NIK 
• t(14;16): MAF (3%) Secondary translocations 
• t(14;20): MAFB (1.5%) • t(8;14): MYC 
Hyperdiploidy • Other non-IGH@ translocations 
• Trisomies of chr 3, 5, 7, 9, 11, 15, 19 and 21 Epigenetic events 
 • Global hypomethylation (MGUS to MM) 
 • Gene-specific hypermethylation (MM to PCL) 
 Molecular hallmarks 
 • Immortalization 
 • G1/S abnormality (CDKN2C, RB1 (3%), CCND1 
(3%) and CDKN2A)) 
 • Proliferation (NRAS (21%), KRAS (28%), BRAF 
(5%) and MYC (1%)) 
 • Resistance to apoptosis (PI3K and AKT) 
 • NF-κB pathway (TRAF3 (3%), CYLD (3%) and 
I-B) 
 • Abnormal localization and bone disease (DKK1, 
FRZB and DNAH5 (8%)) 
 • Abnormal plasma cell differentiation (XBP1 (3%), 
BLIMP1/PRDM1 (6%) and IRF4 (5%)) 
 • Abnormal DNA repair (TP53 (6%), MRE11A (1%) 
and PARP1) 
 • RNA editing (DIS3 (13%), FAM46C (10%) and 
LRRK2 (5%)) 
 • Epigenetic abnormalities (UTX (10%), MLL (1%), 
MMSET (8%), HOXA9 and KDM6B) 
 • Abnormal immune surveillance 
 • Abnormal energy metabolism and ADME events 
(absorption, distribution, metabolism and excretion) 
 Deletions 
 • 1p: CDKN2C, FAF1 and FAM46C (30%) 
 • 6q (33%) 
 • 8p (25%) 
 • 11q: BIRC2 and BIRC3 (7%) 
 • 13: RB1 and DIS3 (45%) 
 • 14q: TRAF3 (38%) 
 • 16q: CYLD and WWOX (35%) 
 • 17p: TP53 (8%) 
Table 2. Genetic events underlying the initiation and progression of MM to PCL 28. 
 
 
ability of the tumor cell to interact with the BM microenvironment 31;32. The contributions of the two 
genes dysregulated by t(4;14) remain controversial. MMSET is a chromatin-remodeling factor that is 
over-expressed in all tumors with a t(4;14), whereas about 20 % of tumors lack der(14) and FGFR3 
expression. The rare acquisition of FGFR3 activating mutations during progression confirms a role for 
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FGFR3 in MM pathogenesis. Although an activated mutant FGFR3 can be oncogenic, it recently was 
shown that wild-type FGFR3 (as is found in most t(4; 14)) can contribute to B cell oncogenesis 33. 
The patterns of spiked expression of genes deregulated by primary IgH translocations and the 
universal over-expression of CCNDs genes led to the translocations and cyclin D (TC) classification that 
includes five groups: TC1 tumors (18%) express high levels of either cyclin D1 (11q13) or cyclin D3 
(6p21) as a result of an Ig translocation; TC2 tumors (37%) ectopically express low to moderate levels 
of cyclin D1 despite the absence of a t(11;14) translocation; TC3 tumors (22%) are a mixture of 
tumors that do not fall into one of the other groups, with most expressing cyclin D2, but a few also 
expressing low levels of cyclin D1 or cyclin D3; TC4 tumors (16%) express high levels of cyclin D2, and 
also MMSET (and in most cases FGFR3) as a result of a t(4;14) translocation; and TC5 tumors (7%) 
express the highest levels of cyclin D2, and also high levels of either MAF or MAFB, consistent with 
evidence that both MAF transcription factors up-regulate the expression of cyclin D2 31;34. 
 
Copy number abnormalities 
Gains and losses of DNA, resulting in copy number alterations, are common events in myeloma.  
Nearly half of MGUS and MM tumors are hyperdiploid (HRD), with 48–75 (mostly 49–56) 
chromosomes, usually with extra copies of three or more specific chromosomes (3, 5, 7, 9, 11, 15, 19, 
21). Non-hyperdiploid (NHRD) tumors have <48 and/or>75 chromosomes. Strikingly, HRD tumors 
rarely (~10%) have a primary IgH translocation, whereas NHRD tumors usually (~70%) have an IgH 
translocation 35. Although it has been proposed that NHRD and HRD tumors represent different 
pathways of pathogenesis, the timing, mechanism, and molecular consequences of hyperdiploidy are 
unknown. In any case, HRD patients seem to have a better prognosis than NHRD patients 36. 
Chromosome 1 aberrations are the most common structural aberrations in MM and mostly involve 
deletions in 1p and ampliﬁcations in 1q21 37-39. These genomic events frequently occur together in 
MM, and each is associated with a poor prognosis 39;40. 
Gain of the chromosome 1q arm (+1q) is an event observed in 35–40% of presenting myeloma cases 
37;39; however, the prognostic value of 1q21 gain in MM remain controversial. To date, the relevant 
genes on 1q21 remain unclear. putative targets of this amplifications include CKS1B and PMSD4 genes, 
mediating cell cicle progression and resistance to bortezomib, respectively 41;42.  
Whole arm deletion or interstitial deletions of the 1p chromosome arm are observed in approximately 
30% of myeloma patients 37;39. Molecular genetics has revealed that two regions of 1p, 1p12 and 
1p32.3, are particularly important in myeloma pathogenesis when deleted. 1p12 may be hemi or 
homozygously deleted and contains the candidate tumour suppressor gene FAM46C 43. The function of 
FAM46C is unknown, although recent sequencing and homology studies have shown that its 
expression is correlated to both that of ribosomal proteins and eukaryotic initiation/elongation factors 
involved in protein translation 43. 1p32.3 may also be deleted and contains the two target genes, FAF1 
and CDKN2C. CDKN2C is a cyclin-dependent kinase 4 inhibitor involved in negative regulation of the 
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cell cycle, whereas FAF1 encodes a protein involved in initiation and/or enhancement of apoptosis 
through the Fas pathway. Homozygous deletion of 1p32.3 is associated with a poor prognosis in those 
receiving ASCT whereas in those receiving nonintensive treatment its prognostic impact is neutral 44. 
Chromosome 13 deletion is observed in approximately 50% of myeloma cases and is commonly 
associated with nonhyperdiploid tumours 45-47. In approximately 85% of cases, deletion of 
chromosome 13 constitutes a monosomy or loss of the q arm, whereas in the remaining 15% various 
interstitial deletions occur 45;46. With this, the identification of key genes contributing to myeloma 
pathogenesis is challenging as often a level of gene function remains from the residual allele(s). 
Despite this, molecular studies have shown that the tumour suppressor gene RB1 is significantly 
underexpressed in del(13/13q) and may therefore result in inferior negative cell cycle regulation 39. 
Historically, del(13) has been associated with an unfavorable prognosis in MM, but there is now 
increasing evidence that its prognostic relevance may be related to its association with other genetic 
aberrations. Recent studies suggest that the prognostic signiﬁcance of monosomy 13 may emanate 
from its close association with the t(4;14)(p16;q32) 48;49. Fonseca et al. 49 suggest a crucial role for 
chromosome 13 deletions as a prerequisite for the clonal expansion of myeloma tumors. 
The deletion of 17p13 in MM presumably leads to the loss of heterozygosity of TP53, a well-
characterized tumor suppressor gene that transcriptionally regulates cell-cycle progression and 
apoptosis 50;51. Deletions of chromosome 17p occur in ~10% of untreated MM tumors, and the 
prevalence increases with disease stage 49;52. The deletion 17p13 has been identiﬁed clinically as an 
indicator of very poor prognosis 49;53;54. 
Many other chromosomal deletions, focal copy number losses, and regions of LOH are seen in 
myeloma. Other important regions of LOH include 11q (the site of the BIRC2 and BIRC3 genes), 16q 
(the site of CYLD) and 14q32 (the site of TRAF3) 55;56. All of these genes are involved in the nuclear 
factor-κB (NF-κB) pathway, indicating that up-regulation of NF-κB signalling is important in myeloma. 
 
Mutations  
Multiple myeloma (MM) is a genomically heterogeneous disease. Multiple mutations in different 
pathways collaborate to alter the biology of plasma cells, changing it in ways that lead to overt disease. 
Over the last 10 years, the use of high-throughput expression technologies has provided insights into 
the molecular basis of the disease individual patients. In particular, global gene and miRNA expression 
and genome-wide DNA profiling have been used alone or in an integrated fashion to investigate the 
genomic instability underlying the biological and clinical heterogeneity of MM 57-59. However, although 
it is true that high-throughput profiling technologies have undoubtedly improved our understanding 
of the biology of MM, next-generation sequencing (NGS) has led to nothing less than a sea change in 
the field. Over the last year, a number of studies have shown that whole-genome (WGS) and whole-
exome sequencing (WES) are cost effective means of identifying protein-coding mutations. Where the 
first allows the unguided entire DNA sequencing of an organism’s genome, WES is the most efficient 
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way to identify genetic variants in protein-coding genes 60. The NGS studies in MM are currently 
mainly based on WES and WGS. In addition to characterizing the recurrent alterations affecting MM, 
NGS analyses have made it possible to investigate genomic changes over time, and led to the detection 
of molecular alterations associated with malignant transformation and tumor progression, suggesting 
the alternation of multiple independent clones during the various disease phases from diagnosis to 
progression.  
Over the last few years, NGS has extended the spectrum of simultaneously detectable alterations and 
provided a comprehensive picture of the disease’s genetic landscape. The general scenario emerging 
from such studies indicates: a considerable number of nonsynonymous variants per patient; few 
recurrently mutated genes of probable pathogenetic significance and a heterogeneous subclonal 
structure at the time of diagnosis 20;22;43;61. Two very recent studies (20;61) made a significant 
contribution to defining reference MM datasets by substantially increasing the number of cases that 
could be queried in order to determine the frequency of the somatic gene mutations revealed by NGS 
studies in larger cohorts (Figure 4). 
Chapman et al. provided the earliest data 43 in a dataset of 38 MM tumors, 23 of which were profiled by 
means of WGS and 16 by means of WES (one by both). Their analysis showed the occurrence of 
approximately 35 WGS detected and 28 WES detected pointwise nonsynonymous mutations in each 
MM tumor that lead to intermediate behavior between that of genetically less-mutated leukemias (<10 
nonsynonymous mutations per sample) 62 and that of more complex solid tumors (up to >500 
nonsynonymous mutations) 63. The high frequency of nonsynonymous variants in MM was confirmed 
by subsequent investigations, which also revealed the greater presence of nonsynonymous mutations 
(missense, nonsense or indel over silent ones (intronic, untranslated or synonimous) 20 and the 
progressive increase of non-silent mutations from asymptomatic to extramedullary disease (namely, 
from <10 to almost 60 median mutations across MGUS, high-risk smoldering MM, MM, and PCL) 26. 
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Figure 4. Summary of the main publications involving next-generation sequencing analysis for variants 
identification and definition of disease clonality in multiple myeloma 64 
 
A further increased mutational load has been observed in myeloma cell lines 65. Among the recurrently 
mutated genes with putative oncongenic role, the most frequent are KRAS, NRAS, TP53, BRAF, TRAF3, 
FAM46C and DIS3, confirming the main involvement of both tirosine kinase receptor and NF-kB 
pathways. Mutations in NRAS, KRAS and TP53 genes are well-known markers of advanced disease in 
MM, and they had been already described as frequent by conventional sequencing 28; overall, they 
occur in up to 50% MM patients if not more. BRAF mutations have been described in 4-14% patients 
20;20;43;61; the data on the percentage of BRAF mutated cases carrying V600E mutation of the gene, 
pathognomonic in B-cell hairy cell leukemia 66 range from about 30 20 to 55% 61. In addition, NGS 
studies further support previous evidence of recurrent (~11-13%) FAM46C mutations in MM 20;43;61; 
although its function is still unknown, correlations have been found with the expression of ribosomal 
proteins, eukaryotic initiation and elongation factors involved in protein translation, prompting for a 
functional role in the regulation of translation. FAM46C maps to 1p12, frequently deleted in MM (more 
than 20% patients), in most of the cases as part of a larger deleted region that extends telomerically to 
the 1p32.3 region, associated with poorer prognosis 67. FAM46C alterations (either incorporating loss-
of-heterozigosity or mutations) were similarly correlated with impaired overall and progression-free 
survival 44. Finally, NGS studies have shown that DIS3, a prevalently nuclear subunit of the human 
exosome complex whose catalytic activity is governed by the endoribonucleolytic (PIN) or 3´–5´ 
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exoribonucleolyitic (RNB) domains, is also recurrently mutated in 11% of MM patients 20;43;61. DIS3 
mutations in MM prevalently affect the RNB domain; preliminary functional analysis suggested that 
MM-associated mutations in DIS3 RNB domain (inhibiting its exonuclease activity) are indeed 
synthetically lethal with inactivation of DIS3 endonucleolytic activity (consequent to the disruption of 
endoribonucleolytic domain functionality), and that DIS3 function cannot be replaced by other 
homolog exosome-associated nucleases 68. Undoubtedly, recurrent mutations in DIS3 and FAM46C 
prompted for further investigation of altered RNA-processing machinery and protein homeostasis 
mechanisms in MM. Additional putative activating mutations that might be relevant in MM 
pathobiology have been described in IRF4 gene, involved in sustaining survival in tumor PCs 69, in 
subset of genes (HOXA9, MLL, MLL2, MLL3, UTX, WHSC1, and WHSC1L1) involved in histone 
modifications 43, in RB1 and CYLD 21;61. 
 
Epigenetic changes 
Although there has been substantial work on the genetics of myeloma, little is known about the 
epigenetic changes that lead to disease progression and their impact on treatment resistance 70. DNA 
can be modified by methylation of cytosine residues in CpG dinucleotides; in addition, chromatin 
structure may be modified by histone modifications, such as methylation, acetylation, phosphorylation 
and ubiquitylation 71. The most important epigenetic change that is relevant to the pathogenesis of 
myeloma is global DNA hypomethylation and gene-specific DNA hypermethylation during the 
transformation of MGUS to myeloma 72. The most pronounced DNA methylation change is seen in the 
15% of patients with the t(4;14) translocation, whose myeloma samples have increased gene-specific 
DNA hypermethylation compared with myeloma samples of other cytogenetic subgroups. This t(4;14) 
subgroup overexpresses MMSET, which encodes a histone methyltransferase transcriptional repressor 
73-75 and its deregulation leads to global changes in histone modifications that promote cell survival, 
cell cycle progression and DNA repair 74. Other chromatin modifiers are also deregulated in myeloma, 
including lysine-specific demethylase 6A (KDM6A; also known as UTX), KDM6B, mixed-lineage 
leukaemia (MLL) and homeobox A9 (HOXA9), but the full relevance of any resultant chromatin 
modifications needs further validation 43. 
 
Micro-RNAs 
MicroRNA (miRNA) genes encode a class of small RNAs (17–25 base pairs) which function to regulate 
the translation of other proteins by forming complementary base parings to specific mRNA transcripts. 
Studies have shown that miRNAs can act as both tumour suppressors and oncogenes in a range of 
cancers and that their transcriptional control is regulated by promoter methylation changes 76. A 
substantial amount of work has been completed to investigate which miRNAs are differentially 
expressed in myeloma 77;78, and it has been shown that miRNA changes can deregulate genes and 
pathways relevant to myeloma pathogenesis including cell cycle progression, TP53 and MYC 79-81. 
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Treatment 
The treatment of MM has so far been unrelated to any particular molecular or genetic feature. The 
cornerstones of conventional anti-myeloma therapy have long been alkylators and corticosteroids, 
more specifically oral melphalan and prednisone (MP), leading to a median post-treatment overall 
survival (OS) of 3-4 years. Subsequently, high-dose therapy followed by autologous stem cell 
transplantation (ASCT) has been introduced into standard practice as it prolongs survival in 
comparison with conventional chemotherapy (median OS 5–7 years) 82 83. However, over the last few 
years, the treatment of MM has changed considerably as a result of drug development 82: in particular, 
the immunomodulatory drugs (IMiDs) thalidomide 84 and lenalidomide 3 85, and the proteasome 
inhibitor bortezomib 86;87, are effective in treating newly diagnosed or relapsed myeloma 83, and have 
further improved overall and event-free survival. However, there is still a lack of effective therapies 
targeting the deregulated biological pathways specifically associated with the disease. 
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PLASMA CELL LEUKEMIA 
 
Definition and epidemiology 
Plasma cell leukemia (PCL) is the most aggressive presentation of the PC neoplasms and is 
characterized by circulating plasma cells > 2×109/L in peripheral blood or by a relative plasmacytosis 
> 20% of blood leukocytes 88;89. While primary disease (pPCL) presents as de novo leukemia, 
secondary leukemic transformation (sPCL) arises from pre-existing multiple myeloma (MM) 90;91 
probably as a consequence of clonal transformation. PCL is rare. sPCL occurs in only 1.8–4% of MM 
patients and pPCL occurs with a comparable incidence. Consequently, few large studies of PCL patients 
have been reported 90-92 and the molecular basis of PCL remains poorly understood. Around 60% of 
patients presented a primary form and the remainder 40% occurred as complication during the course 
of MM 93. The median age of patients with pPCL ranged between 52 and 65 years, about 10 years 
younger than the median age of 65 to 70 years observed in the general myeloma population 2 and in 
secondary PCL 52. 
 
Presenting clinical features 
Primary PCL has a more aggressive clinical presentation than MM including a higher tumor burden. 
Patients may present with symptoms due to profound anemia, hypercalcemia and thrombocytopenia. 
On physical examination, patients may exhibit a higher prevalence of organomegaly with involvement 
of the liver, spleen, lymph nodes, central nervous system and palpable extramedullary soft-tissue 
plasmacytomas. In contrast, the presence of lytic bone lesions is lower than that observed in MM 52. 
Also, reflecting this aggressive clinical presentation, a higher proportion of patients with primary PCL 
have significant leukocytosis, as well as elevated lactate dehydrogenase (LDH) and β2-microglobulin 
serum levels. 
 
Genetics of PCL 
Cytogenetic studies show that plasma cells in primary PCL have a number of genetic abnormalities. 
 
Ploidy status 
More than 80% of patients with PCL have hypodiploid or diploid cells which is associated with poor 
prognosis whereas about 60% of patients with MM display hyperdiploidy, a favorable finding 94.  
 
IGH translocations 
Chromosome 14q32 translocations are found in a great number of pPCL and sPCL patients (82–87%), 
as would be expected in NH-MM cases. Based on the study by Tiedemann and colleagues 52, in pPCL 
IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, 
while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 
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16q23 (MAF), recapitulating MM 52. Genomic aberrations such as t(4;14), del(13q14), del(17p), 
del(1p21) and 1q21 gains are adverse risk factors in MM but their significance in PCL is unclear (as 
they usually indicate more aggressive behavior which is ubiquitous in PCL) 54;59;95;96.  
 
Chromosome 13 
In a series of 26 patients Garcia-Sanz reported deletion of chromosome 13 in 84% of patients with PCL 
versus 26% for those with MM 94. In the Mayo study loss of 13q by FISH was found very common in 
pPCL (85%), more so than in MM (54%) (P = 0.02); but with no difference in prevalence between pPCL 
and sPCL 52. As would be expected in NH-MM Avet-Loiseau reported a high frequency of monosomy 13 
(85%) 92. 
 
Deletions of 17p13 and TP53 inactivation 
Previous studies reported 17p13.1 deletion in MM as a late event found only in 10% of patients 53, and 
TP53 coding mutations in only 3% 97. In the group of 80 patients reported by Tiedemann there was a 
prevalence of deletion of 17p13.1, causing allelic loss of TP53, in 50% of pPCL and a remarkable 75% 
of sPCL. Moreover, functionally relevant TP53 coding mutations were identified in 24% of PCL patients 
tested, contributing to a substantial prevalence of allelic TP53 inactivation (by mutation or deletion) of 
56% in pPCL and 83% in sPCL. Eleven percent of pPCL and 33% of sPCL tumors showed biallelic 
inactivation of TP53 with simultaneous allelic deletion and mutation 52. Interestingly, monoallelic or 
biallelic inactivation of TP53 did not correlate significantly with survival in sPCL, unlike MM, where 
del(17p13.1) predicts adverse survival 98. Lack of correlation between TP53 status and survival may 
reflect ubiquitous targeting of the TP53 pathway in sPCL. 
 
MYC abnormalities and RAS mutation 
Rearrangement of MYC was identified by 3’FISH break apart in 33% of pPCL and sPCL tumors and was 
complemented by MYC amplification or 5’MYC translocations in 8 and 17% of patients, respectively 52. 
MYC rearrangements were associated with a trend toward inferior OS in pPCL (median OS of 8.6 
versus 27.8 months without rearrangements, P = 0.006). On the other hand, mutations of K-RAS or N-
RAS at codons 12, 13 or 61, previously characterized as functionally activating 99;100 101, were found in 
27% pPCL and 15% sPCL 52. Activating mutations of RAS were associated with a trend toward poorer 
outcome in pPCL (P = 0.069). However, the prevalence of K- or N-RAS mutation in sPCL is comparable 
to that reported in MM (21%) 101, suggesting little, if any, selective pressure for RAS activation in 
secondary leukemic transformation from MM. 
 
Survival 
The survival of patients with pPCL is short. In seven series, historically median survival, without novel 
therapies, has ranged from 6.8 to 12.6 months 52;90;91;94. Furthermore, the median survival of 231 
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patients from a recently published epidemiology study was only 4 months 102. Of note, the survival rate 
at 5 years from diagnosis is less than 10% in all series. 
The best survival data, incorporating hematopoietic stem-cell transplantation, reported a median 
survival longer than 3 years 103. Unfortunately, the significant improvement in survival observed in 
MM in the past decade has not been seen in PCL 102. 
These discouraging survival results in primary PCL are due to two facts: 1) its aggressive presentation 
with severe complications leading to early death within the first months from diagnosis, and 2) the 
lack of effective therapy to achieve sustained responses. Early mortality is still of concern and reflects 
the aggressiveness of the disease 92.  
 
Treatment of PCL 
Treatment of both pPCL and sPCL, as in MM, is aimed at prolonging survival and maximizing quality of 
life, as there are no recognized curative regimens 104. In general, patients are treated with aggressive 
induction therapy followed by ASCT in those who are appropriate candidates for this approach. 
Chemotherapy alone is the principal option for those ineligible for ASCT. The best induction regimen 
for PCL is not known and there is great variability in clinical practice. Several combinations that 
include an alkylating agent have been used as sole treatments of PCL or as induction therapy prior to 
anticipated transplant. Combinations that include melphalan are generally avoided as induction 
therapy in potential transplant candidates to allow adequate stem cell collection. Most patients need to 
be treated with the most effective agents currently available 105;106 and historic data with older agents 
show poor rates of control. 
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DIS3: A KEY COMPONENT OF THE EXOSOME COMPLEX 
 
DIS3 gene encodes a highly conserved ribonuclease which serves as the catalytic component of the 
exosome complex involved in regulating the processing and abundance of all RNA species. DIS3 gene 
map on chromosome 13q22.1 and it is composed by 22 exons.  
The multisubunit RNA exosome complex is a major ribonuclease of eukaryotic cells that participates in 
the processing, quality control and degradation of virtually all classes of RNA in Eukaryota 107. 
 
The exosome structure 
The eukaryotic exosome is composed of ten to eleven subunits, which can be divided into two major 
groups with regard to their structural and functional contributions. The ﬁrst group encompasses nine 
proteins that form the ‘exosome core’. They are all rather small polypeptides with molecular masses of 
20–50 kDa. Three of these are built entirely of RNA binding domains and motifs, whereas the 
remaining six are single-domain proteins homologous to RNase PH, a homomultimeric enzyme found 
in Escherichia coli. The second group of exosome components comprises two subunits, DIS3 and Rrp6, 
which associate with the core in different combinations, giving rise to isoforms of the complex. DIS3 
and Rrp6 are both large multi-domain polypeptides with molecular masses around 100 kDa. They are 
quite different from each other and carry all catalytic activity of a typical eukaryotic exosome. The 
repertoire of catalytic subunits shows considerable diversity in different groups of Eukaryota, much 
more than the core subunits. The schematic structure of the eukaryotic RNA exosome is reported in 
Figure 5 107. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Side view of the eukaryotic RNA exosome 
with the hexamer in blue, the cap in magenta and the 
associated ribonucleolytic subunits in green (DIS3) 
and yellow (Rrp6). Endo- and exonuclease active sites 
are denoted in deep red 107 
 
The exosome core 
The structure of the exosome core is well established, owing to the crystal structure obtained for the 
Homo sapiens complex 108. Its nine subunits are arranged in a two-layered ring; the bottom layer is 
formed by six subunits homologous to bacterial RNase PH: Rrp41, Rrp42, Rrp43, Rrp45, Rrp46 and 
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Mtr3, and referred to as the ‘hexamer’, while the top layer consists of the three RNA binding subunits, 
Rrp4, Rrp40 and Csl4, and is called the ‘cap’ (Figure 6). Rrp4 and Rrp40 each contain one S1 and one 
KH RNA binding domain, and Csl4 consists of a KH domain and a zinc ribbon RNA binding motif. The 
cap subunits do not form contacts with one another but instead each is ﬁrmly attached to two subunits 
of the hexamer 108. The central channel that traverses the ring is only wide enough to accommodate 
single-stranded RNA (ssRNA). 
The architecture of the exosome core is ancient and perhaps even predates the exosome itself as two 
complexes of prokaryotic origin have the exact same domain composition and spatial arrangement. 
One is the exosome found in most Archaea, sometimes called the ‘exosome-like complex’ 109;110 and the 
other is polynucleotide phosphorylase (PNPase) found in Eubacteria as well as in plant and vertebrate 
mitochondria 111. 
 
 
Figure 6. Architecture and subunit Interactions within the human 
exosome 108 
 
 
The exosome ribonucleases 
DIS3 
DIS3 proteins are homologous to RNase II and RNase R of E. coli, which makes them members of the 
RNR superfamily 112. The RNR homology region of DIS3 proteins has the typical domain layout: two 
cold-shock domains (CSDs), an RNB domain and an S1 domain. CSD and S1 are ancient folds that non-
speciﬁcally bind RNA, while RNB is a catalytic domain endowed with processive exoribonuclease 
activity. A distinguishing feature of the DIS3 family is a CR3 motif and a PIN domain located N-
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terminally to the RNR region 113-115. The PIN active site consists of four acidic amino acid residues but, 
unlike in RNB, they are dispersed throughout the otherwise weakly conserved sequence of the domain. 
The CR3 motif is named for its three conserved cysteine residues, but it also contains a conserved 
histidine residue. Although details are not clear, the motif also plays a role in the core–DIS3 interaction 
and is required for some of the cellular functions of the exosome 113. DIS3 is an endoribonuclease and a 
3’–5’ exoribonuclease. The endonuclease activity resides in the PIN domain, the active site of which is 
exposed to the solvent and consists of four acidic amino acid residues that coordinate two divalent 
metal cations (preferably manganese) 114-116. The enzyme cannot cleave dsRNA but both circular and 
linear ssRNA are eligible substrates. A preference for substrates with phosphorylated 5’ termini has 
been reported 116. The exonuclease activity of DIS3 depends on four conserved aspartate residues that 
coordinate two magnesium cations to hydrolytically cleave the RNA backbone. Mutation of any one of 
these residues completely abolishes the activity 108;117. The active site is located in the RNB domain, 
buried at the bottom of a narrow channel and can only be reached by ssRNA at least 7 nt long 118. DIS3 
exonucleases are highly processive. They attack 3’ ends of ssRNA and once bound they degrade 
substrate completely, releasing nucleoside 5’-monophosphates and leaving end products a few 
nucleotides long (this length varies slightly from one homologue to another)119. 
The human genome encodes three DIS3 homologues, of which only hDIS3 and hDIS3L were found to 
associate with the exosome 119;120. Notably, both of them are processive 3’–5’ hydrolytic exonucleases, 
whereas only hDIS3 has also retained endonuclease activity in its PIN domain. In vivo localization 
studies and analyses of substrate speciﬁcities revealed that hDIS3L is restricted to the cytoplasmic 
exosome, whereas hDIS3 is mainly a nucleoplasmic protein, with a small fraction present in the 
cytoplasm 119;120.  
The third human DIS3 homologue —hDIS3L2— does not interact with the exosome core, due to the 
lack of PIN domain and it has been recently demonstrated by several independent studies that it is 
responsible for an alternative 3’–5’ RNA decay pathway in the cytoplasm 121;122. An important role of 
hDIS3L2 in the maintenance of proper cellular metabolism is supported by the fact that mutations in 
its gene were found to be associated with Perlman syndrome of overgrowth and predisposition to 
Wilm’s tumor development 123. 
 
Rrp6 ribonucleases 
Rrp6 proteins belong to the large DEDD superfamily of nucleases, which includes enzymes of various 
functions, e.g. oligoribonuclease and proofreading domains of DNA polymerases 112. Rrp6 proteins are 
distributive 3’–5’ exoribonucleases that cleave RNA hydrolytically and release nucleoside 5’-
monophosphates 124. Activity comes from the conserved DEDD domain, whose active site is solvent 
exposed 125;126 and consists of four conserved acidic amino acid residues coordinating two magnesium 
cations. The combination of a distributive mode of action with selectivity for ssRNA should preclude 
digestion of structured substrates. Surprisingly, Rrp6 proteins are able to break down structured 
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substrates provided there is a single stranded region upstream of the structure 125. This effect is 
slightly stronger for the human protein than for the yeast one. The mechanistic background for this 
activity is unknown. 
 
Isoforms of the exosome 
The exosome core displays little structural variability across Eukaryota. All core subunits have the 
same subcellular localization in S. cerevisiae and H. sapiens 119;120. They are found in the cytoplasm and 
the nucleus, more concentrated in the latter, and enriched in nucleoli. In contrast to core subunits, 
some of the associated subunits are compartment-speciﬁc and give rise to different isoforms of the 
exosome. In S. cerevisiae DIS3p has the same localization pattern as the core, whereas Rrp6p is 
restricted to the nucleus 124. This implies that the S. cerevisiae exosome exists in two isoforms: a ten-
subunit cytoplasmic one (core +DIS3p) and an eleven-subunit nuclear one (core + Rrp6p +DIS3p).  
The H. sapiens genome contains three homologues of the yeast DIS3 gene. However, since one of them 
(DIS3L2) does not encode a full PIN domain, the DIS3 protein family only has two human members: 
DIS3 and DIS3-like (DIS3L). DIS3 has greater homology to yeast DIS3p than DIS3L does, but the domain 
composition is the same in both paralogues 119;120. 
Moreover, the subcellular localization of the two human paralogues is radically different: while DIS3L 
is strictly cytoplasmic, DIS3 is largely limited to the nucleus with only a small fraction in the cytoplasm. 
Notably, while the core subunits adhere to the usual subcellular distribution of exosome proteins, DIS3 
is absent from nucleoli119. 
As in S. cerevisiae, human RPR6 is nuclear with the typical nucleolar enrichment. In addition, small 
quantities are also present in the cytoplasm 119. 
Taken together, three major exosome isoforms appear to exist in human cells: core+RRP6 in the 
nucleolus, core+RRP6+DIS3 in the nucleoplasm and core+DIS3L in the cytoplasm. Other possible, less 
abundant isoforms are: nucleoplasmic core+DIS3 and cytoplasmic core+DIS3, core+RRP6+DIS3 and 
core+RRP6+DIS3L and core+RRP6. 
 
Speciﬁc functions of the RNA exosome 
The exosome plays a fundamental role in most RNA metabolic pathways 114;127 (Figure 7). 
These pathways include turnover of normal mRNAs and AU-rich element-regulated decay of unstable 
mRNAs 128;129; nuclear processing of stable RNA classes (small nuclear RNA (snRNA), small nucleolar 
RNA (snoRNA), rRNA, tRNA)130;131; degradation of unstable transcripts arising from intergenic regions 
122 and complete degradation of mRNA after endonucleolytic cleavage initiated by small interfering 
RNA (siRNA) in RNA interference 132. 
Furthermore, the exosome plays a crucial role in the quality control, as it is a primary enzyme 
degrading unwanted molecules in the nucleus and the cytoplasm, including incorrectly processed pre-
mRNAs, rRNAs and tRNAs as well as translationally incompetent mRNAs 130;131. 
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Figure 7. Map of the exosome's cellular functions 107 
 
Apart from its well-documented role in RNA metabolism, a recent study has implicated the exosome in 
the activation-induced immunoglobulin heavy-chain class switch recombination and immunoglobulin 
variable region somatic hypermutation in human B lymphocytes 133. It was also suggested that the 
exosome is essential for activation-induced cytidine deaminase (AID) recruitment to chromatin, but 
the mechanistic details of this process remain elusive 133. 
 
Impact of DIS3 mutations in multiple myeloma 
Recent next generation sequencing (NGS) studies observed an increase of single nucleotide variants 
(SNVs) and a change in the genetic landscape of multiple myeloma 20;21;26. However, speciﬁc gene 
mutations occurring in a signiﬁcant percentage of cases are rare events in MM.  
One of the novel ﬁndings of the ﬁrst myeloma genome publication was the identiﬁcation of DIS3 
mutations in 11% of myeloma samples. Chapman et al. provided the earliest data 43 in a dataset of 38 
MM tumors, showing an occurrence of DIS3 mutations of 10.5%. The four mutations observed by 
Chapman et al occur at highly conserved regions and cluster within the RNB domain facing the 
enzyme’s catalytic pocket (Figure 8).  
 
 
Figure 8. Alignment of human, yeast and bacterial RNB domain of DIS3. Positions of observed mutations are 
indicated with respect to the human sequence 43 
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Two lines of evidence indicate that the DIS3 mutations result in loss of function. First, three of the four 
tumours with mutations exhibited loss of heterozygosity via deletion of the remaining DIS3 allele. 
Second, two of the mutations have been functionally characterized in yeast and bacteria, where they 
result in loss of enzymatic activity leading to the accumulation of their RNA targets 134. Given that a key 
role of the exosome is the regulation of the available pool of mRNAs available for translation 135, these 
results indicate that DIS3 mutations may dysregulate protein translation as an oncogenic mechanism 
in multiple myeloma.  
The presence of mutations in DIS3 was subsequently confirmed by Walker et al 26, that performed NGS 
analysis on 22 MM patients identifying 4 mutations in this gene. They found that the proportion of 
affected samples was higher (18%) than Chapman et al 43. This difference was due of the samples 
analyzed, because DIS3 mutations have been found exclusively in t(4;14) or t(11;14) samples, of which 
their dataset was composed.  
A further study 61 reported that DIS3 gene is subject to point mutations with LOH, strongly implicating 
DIS3 as a tumor suppressor gene in 11% of MM patients (Figure 9). Interestingly, they reported that 
DIS3 aberrations were more commonly seen among nonhyperdiploid MM cases compared to the 
hyperdiploid cases.  
 
 
Figure 9. Signiﬁcantly Mutated Genes in 203 Patients with MM 61 
 
Bolli et al 20 studied by NGS a large cohort of myeloma patients, with overrepresentation of advanced 
disease, hyperdiploid and del(17p) cases and underrepresentation of t(11;14) and t(4:14). This may 
explain the low frequency of DIS3 mutations (1.5%) found, mostly present in IGH rearranged cases 
43;136. 
Finally, Weissbach et al 137performed deep amplicon sequencing of entire coding region of DIS3 in a 
uniformly-treated cohort of 81 MM patients. They detected a frequency of DIS3 mutations of 11%, in 
agreement with previous sequencing studies that did not select for cases with IGH-translocations 43;61. 
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The majority of mutations found in MM affect conserved residues in the hDIS3 RNB domain, suggesting 
their impact on the exonucleolytic activity of the enzyme 68 (Figure 10). In contrast, point mutations in 
the PIN domain appear to have only low effects on cell growth 68, although the PIN domain possesses 
endonucleolytic function and is necessary as a structural element for the association of the exosome in 
yeast 68;115;116.  
Figure 10. Frequency of SNVs in domain of DIS3 from the literature 137. 
 
Experimental results from the yeast model made by Tomecki et al 68, revealed the importance of DIS3 
and intactness of its RNB domain for RNA metabolism, protein function and cell physiology, leading to 
vulnerabilities that can be used for anti-cancer drug development. 
Among the molecular phenotypes caused by MM mutations, there are strong effects on the ability of 
the enzyme to exonucleolytically digest RNA substrates, leading to increased levels of extended 5.8S 
precursor molecules, improperly processed at the 3’-end, and a decreased degradation rate of RNA 
molecules belonging to other RNA classes, such as tRNAs and their precursors, snRNAs and other 
small RNAs, including RNase P RNA and 7SL RNA. Moreover, experimental results from DIS3 
mutations in the yeast model corresponding to those found in MM patients, cause cell growth defects 
and molecular phenotypes strongly suggesting impaired exosome function 68. 
Next, Tomecki et al 68 checking whether, as in yeast, there is a synergistic effect of MM-associated RNB 
domain mutations and dysfunction of hDIS3 PIN domain endonuclease activity: the metabolic activity 
of the cells bearing mutations in the RNB domain was also additionally reduced on accompanying 
inactivation of PIN domain endonuclease, while the inactivation of the PIN domain catalytic activity 
alone did not lead to accumulation of 5.8S rRNA precursors.  
In conclusion, although the molecular events linking the inactivation of hDIS3 nucleolytic properties 
and its inability to efﬁciently degrade transcripts with reduced cell viability remain to be elucidated, 
the negative synthetic interaction between MM-associated RNB domain mutations and PIN domain 
dysfunction may suggest the latter as a promising drug target for cancers bearing mutations that affect 
hDIS3 RNB domain exonucleolytic activity. 
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Involvement of DIS3 gene in others cancers 
DIS3 gene mutations were found in global screens not only in multiple myeloma patients, but also in 
other type of cancers, such as adenoid cystic carcinoma 138 and colorectal cancer 139. Recently, Ding et 
al 25 reported that DIS3 is among the most recurrently mutated genes in AML. Additionally, hDIS3 was 
identiﬁed in transcriptomic analyses as one of the genes, whose expression differentiates superﬁcial 
spreading melanoma from nodular melanoma 140. DIS3 overexpression was earlier observed in human 
colorectal cancer and in a mouse model of this cancer, where elevated levels of respective mRNA and 
protein positively correlated with the incidence of metastasis 141. Expression proﬁling revealed that 
hDIS3 is among several genes whose loss-of-function signiﬁcantly reduces viability of colorectal 
carcinoma cell lines 141. Increased levels of hDIS3 mRNA have been also recently proposed as one of 
the characteristics of the epithelial ovarian cancer 142.  
All examples presented above strongly suggest the existence of possible molecular link between hDIS3 
functions and development of different cancers 143. More speciﬁcally, it appears likely that 
exonucleolytic activity of hDIS3 protein —the major catalytic subunit of the exosome— might be 
somehow involved in this association.  
  
28 
 
Aim of the study 
To gain more insights into the molecular relevance of DIS3 mutations in MM pathogenesis and 
progression, we performed deep sequencing of the PIN (exons 1-4) and RNB (exons 10-18) functional 
domains in a retrospective cohort of 130 cases with MM at onset, 17 at relapse (of whom 15 were also 
tested at onset), 24 patients with primary PC leukemia (pPCL), 12 with secondary PCL and 20 multiple 
myeloma cell lines. Moreover, we correlated the overall DIS3 mutation status in relation to the most 
recurrent chromosomal abnormalities (as assessed by fluorescence in situ hybridization) as well as the 
occurrence of DIS3 mutations in major and minor subclones. Additionally, to investigate the state of 
DIS3 mutation longitudinally, we analyzed samples of 20 patients for whom bone marrow specimens 
were collected at two different time points. We also performed deep sequencing of cDNA of the DIS3-
mutated cases to verify if the mutations detected on genomic DNA are also expressed at transcriptomic 
level. DIS3 mutation was also integrated with gene expression profiles in MM samples in order to 
identify transcriptomic profiles possibly related to DIS3 mutations. Finally, in the 16pPCL patients for 
whom the follow-up was available, the association of DIS3 mutations with clinical outcome was tested. 
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Materials and Methods 
Patients and cell lines 
Pathological bone marrow specimens from 130 cases with MM at onset (66 males, 64 females; median 
age 67 years, range 42–85 years), 17 at relapse (8 males, 9 females; median age 67 years, range 47–79 
years) and 12 MM patients at leukemic transformation (4 males, 8 females; median age 69 years, range 
54–82 years) were obtained during standard diagnostic procedures after the patients had given their 
informed consent according to institutional guidelines. Many of the patients included in this study 
have been described in our previous reports 58;144. Additionally, we analyzed 24 primary plasma cell 
leukemia (pPCL) cases at onset, of whom eight (4 males, 3 females; median age 57 years, range 50–72 
years) admitted to our hematology service and 16 included in a multicenter clinical trial (RV-PCL-PI-
350, EudraCT N°2008-003246-28) aimed at evaluating safety and anti-tumor activity of combined 
lenalidomide and dexamethasone as ﬁrst-line treatment 145. 
Seventy-eight patients had an immunoglobulin (Ig) G protein monoclonal component, 33 IgA and one 
IgG/IgA protein; 48 cases expressed λ light chain and 78 κ chain. The diagnoses were made by means 
of conventional morphology and immunophenotype analyses and the patients were clinically staged 
according to previously described criteria 146. No conventional cytogenetic (G-banding) analyses were 
available. Plasma cells were puriﬁed from the bone marrow samples as previously described 147;148. 
The purity of the selected PC populations was assessed by means of morphology and ﬂow cytometry, 
and was >90% in all cases. 
Human myeloma cell lines (HMCLs) were purchased from DSMZ-German Collection of Microorganisms 
and cell Culture, Germany (NCI-H929, OPM2, JJN3,and KMS-12), kindly provided by Dr. T. Otsuki, 
Kawasaki Medical School, Okayama, Japan (KMS-28, KMS-34, KMS-18,KMS-11, KMS-26 and KMS-27), 
Dr S. Iida, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan(AMO1), Dr. G. 
Tonon, San Raffaele Scientific Institute, Milan (RPMI 8226, delta-47, SK-MM-1 and UTMC-2), Dr. F. 
Malavasi, Department of Genetics, University of Torino, Italy (LP-1), and Dr. P.F. Tassone, Magna 
Graecia University, Catanzaro, Italy (MM.1S and U266), or established in our own laboratory (CMA-03 
and CMA-03/06) 149. 
 
FISH analyses 
All samples were characterized by fluorescence in situ hybridization (FISH) for the main genomic 
aberrations: IGH translocations (t(4;14)(p16.3;q32); t(11;14)(q13;q32); t(14;16)(q32;q23); 
t(6;14)(p21;q32) and t(14;20)(q32;q11)), del(13)(q14), del(17)(p13), hyperdiploidy,1p33 (CDKN2C) 
loss and 1q21.3 (CKS1B) gain. 
FISH analysis for the detection of 13q14 and 17p13 deletions, hyperdiploidy, t(4;14), t(11;14), 
t(14;16), t(14;20) and aberrations of chromosome 1 were performed using the protocol provided by 
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the manufacturer of the multicolor probes LSI D13S19/LSI 13q34, LSI TP53/CEP17, LSI 
D5S23/D5S721/CEP9/CEP15, LSI IGH/FGFR3, LSI IGH/CCND1 (XT), LSI IGH/MAF (Vysis Inc., 
DownersGrove,IL), IGH/MAFB Plus and CKS1B/CDKN2C (P18) (Cytocell Ltd, Cambridge, UK), 
respectively. To investigated the t(6;14), we performed dual-color FISH using the 973N23 clone 
(specific for CCND3) in combination with PAC clone 998D24 (specific for IGH locus). The clones were 
selected by browsing the University of California, Santa Cruz (Santa Cruz, CA) Genome Database 
(http://genome.ucsc.edu/).  
The cut-off levels considered were 10% for fusion or break-apart probes and 20% for numerical 
abnormalities, as recommended by the European Myeloma Network (EMN). 
 
DNA extraction and quantification 
Genomic DNA was extracted using Wizard genomic puriﬁcation DNA kit (Promega Corporation, 
Madison, WI, USA) according to the instructions of the manufacturer and eluted in TE. The 
concentration of DNA extracted was assessed by spectrophotometric quantification with Nanodrop 
(Thermo Fisher Scientific Inc, Waltham, MA, USA). All genomic DNA was stored at −20°C until use. 
 
Mutation analyses 
After DNA extraction and quantification, all samples were subjected to PCR amplification and deep 
sequencing by the 454 GS Junior System (454 Life Sciences, Branford, CT, and Roche Applied Sciences, 
Indianapolis, IN). The 454 GS Junior technology is derived from the technological convergence of 
emulsion PCR and pyrosequencing. Genomic DNA was amplified using special fusions primers 
(spanning exons from 1to 4 for the PIN domain and exons from 10 to 18 for the RNB domain; 
RefSeqNM_014953.4) containing genome-specific sequences (reported in Table 3), and an universal 
tails at the 5’ end to allow the addition of specific MIDs (multiplex identifier sequences used to 
differentiate samples being run together on the same plate) in a second PCR round (Figure 10). 
 
exon Primer FWD Primer REV 
ex_1 5’-GAAAGGGAAGAACCTCCGGG-3’ 5’- TCCCTGTCATACCCCCTTGT-3’ 
ex_2 5’- GCTTCTTGGCTTAACTTATTCAGTG-3’ 5’- ACAGGAACCCTCTCCCGAA-3’ 
ex_3 5’- TGCTAAGAGTTTTCACATATCCTTG-3’ 5’- TCACATGAAGTTATATAGGACTACGA-3’ 
ex_4 5’- AGGCTGTAGTGATGTGTAATTGC-3’ 5’- GCTTACCCACCGACATTCC-3’ 
ex_10 5’- TATGTTGTAGTTGTGCTTTGGAAAT-3’ 5’- CAATATGCTTGACTGGGTAAATGTA-3’ 
ex_11 5’- TTTGCTTGTTAATTACTCTTGTGAAG -3’ 5’- TTCATGGCCGTTTAAGAATC-3’ 
ex_12-13 5’- TTATGGCTAAGTAATCTGTGGTTCTA -3’ 5’-AAATTAGAGATTAATAGCCATGAAACG-3’ 
ex_14 5’- GTAGTGAAAGTAGGAGGACATATTG-3’ 5’- GAAGCTAGAAGAAACAGGAGTCT-3’ 
ex_15 5’- ACACTTGCTGTAGTCATTGTCTT-3’ 5’- GCAAGCCAAATAAAGTAGAAATCAT-3’ 
ex_16 5’- GCGGAGTAACTGAGAGATGAAAG-3’ 5’- CAGGTAGATCAAAACACAAATAGATG-3’ 
ex_17 5’- GCCGAATCTCCTACTTTTCCA-3’ 5’- CCAAAAGCCGATGAACAATGA-3’ 
ex_18 5’- CTTAGCGTCTCCAATATACACACA-3’ 5’- CTAGCAGTATCGACAAAAGGCA-3’ 
Table 3. Genome-specific primers for amplicon library preparation. 
31 
 
 
Figure 10. Schematic representation of the PCR reaction components for the 
preparation of a two step Universal Tailed Amplicon Library. A) First step, targeting the 
template-specific sequences and adding the universal tail. B) Second step, targeting the 
universal tail and adding the 454 Sequencing System primers and MIDs. 
 
PCR reactions were run in 25μl reaction volumes, containing 10 mmols dNTPs, 10 μM of each primer, 
2.5 μl PCR buffer, 12,5 ng DNA, and 0.25 μl of FastStart HiFi Polymerase (Roche Diagnostics). Amplicon 
library A and B sequencing adapters and multiplex identifier (MID) tags were then added to both tails 
of amplicons by a second amplification step. PCR conditions were as follows: in the first amplification 
step, denaturating step at 94°C for 5 min followed by 25 cycles at 94°C (30 sec. per cycle), annealing 
step at 53°C (for exon 1), 57°C (for exons 10, 11 and 17), at 58°C (for the remaining exons) (30 sec. per 
cycle), and extension at 72°C (45 sec. per cycle), followed by a final 7 min. extension at 72°C; in the 
second amplification step, denaturating step at 94°C for 5 min followed by 25 cycles at 94°C (20 sec. 
per cycle), annealing step at 55°C (20 sec. per cycle), and extension at 72°C (45 sec. per cycle), 
followed by a final 10 min. extension at 72°C. 
PCR products were visualized on agarose gel, purified using Ampure-XPDNA-binding paramagnetic 
beads (Agencourt Bioscience Corp., Beckman Coulter S.p.A, Milan, Italy), and quantified in 96-well 
format using picogreen dye (Life Technologies) and the Victor X2 (Perkin Elmer) fluorometer. 
Samples were then diluted to an approximate concentration of 1 × 109 molecules/μL and pooled at 
equimolar concentrations to create a highly multiplexed amplicon library. After pooling, the library 
was further diluted to 106 molecules/µl and subjected to emulsion PCR (emPCR) at a ratio of 0.8 
molecules per bead using the 454 GS Junior Titanium Series Lib-A emPCR Kit (Roche Diagnostics), 
according to the manufacturer’s protocols. Following emPCR, the captured beads with bound DNA 
were enriched with a second DNA capture mechanism to separate out beads with and without bound 
emPCR products. 
A mean of 500.000 enriched beads was used for massively parallel pyrosequencing in a Titanium 
PicoTiterPlate® (PTP) with Titanium reagents (Roche Diagnostics), on the GS Junior instrument, 
32 
 
according to the 454 GS Junior Titanium Series Amplicon Library Preparation Method Manual 
(available online: www.454.com). The obtained sequencing reads were mapped to the reference 
sequence (RefSeqGRCh37.p13) and analyzed by the Amplicon Variant Analyzer (AVA) software 
version 3.0 (454 Life Sciences) to establish the mutant allele frequency. 
The presence of each obtained non-synonymous variant was verified in an independent PCR product, 
analyzed by conventional sequencing whenever the sensitivity of the Sanger’s method was consistent 
with the variant allele frequency. NGS analysis was repeated in cases of mutations in less than 10% of 
the DNA molecules to differentiate real mutations from low-level errors introduced during PCR 
ampliﬁcation and sequencing. To exclude germline variants we sequenced the matched normal DNA, 
when available, or consulted the Human dbSNP Database at NCBI (Build 142) 
(http://www.ncbi.nlm.nih.gov/snp),and removed from the analysis changes present in germline 
samples or with a corresponding rs entry (unless the same variant was also included in NCBI ClinVar 
database). Additional information about the functional relevance of the detected SNVs were obtained 
using five tools which predicts possible impact of amino acid substitutions on the structure and 
function of human proteins using straightforward physical and evolutionary comparative 
considerations. The functional predictors used were Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/), Mutation Taster (http://www.mutationtaster.org/), 
Mutation Assessor (http://mutationassessor.org/), SIFT (http://sift.jcvi.org/) and LRT 
(http://www.genetics.wustl.edu/jflab/lrt_query.html). 
 
Validation of DIS3 variants at transcriptomic level 
To verify the occurrence of DIS3 variants at transcriptomic level, total RNA of mutated samples was 
converted to cDNA using M-MLV reverse transcriptase (Invitrogen) and random examers, and 
subjected to deep sequencing of the exon harboring the variant/s detected on genomic DNA. 
Sequence-specific exonic PCR primers were designed in the Primer 3 program 
(http://frodo.wi.mit.edu/primer3/) and are as follows: 
 
amplicon Primer FWD Primer REV 
ampl_A 5’-CCGGGGTTAGGCGTATTCTA -3’ 5’- AAGTGAGAAATCGCAGTGCC -3’ 
ampl_B 5’- TACTTGCTGCCCGACACTAA -3’ 5’- GGAATACCAGCTTTCACTTGTG -3’ 
ampl_C 5’- ATGTTCCCCATCAGCCTTTT -3’ 5’- AAAATGTGACGTGGACAGGC -3’ 
ampl_D 5’- GGGAAATGAATCACAATGCTGA -3’ 5’- TCTGAACATGCTCTGCTTCG -3’ 
ampl_E 5’- AGTCTTTGGATCAGGCCGAA -3’ 5’- GGCTATTGGGGCTGACTGTA -3’ 
ampl_F 5’- ACTATGGCTTAGCGTCTCCA -3’ 5’- AACGTGCATCAGTGGCTTTT-3’ 
 
Gene expression profiling 
102 MM samples underwent gene expression profiling (GEP) analysis. Total RNA was puriﬁed using 
the RNeasy® Total RNA Isolation Kit (Qiagen, Valencia, CA). Preparation of DNA single-stranded sense 
target, hybridization to GeneChip® Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA) and scanning of 
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the arrays (7G Scanner, Affymetrix) were performed according tothe manufacturer’s protocols. The 
raw intensity expression values were processed by Robust Multi-array Average procedure, with the 
re-annotated Chip Deﬁnition Files from BrainArray libraries version 18.0.0 150, available at 
http://brainarray.mbni.med.umich.edu. Supervised analyses were performed using Signiﬁcant 
Analysis of Microarrays software (SAM version 4.00; Excel front-end publicly available at http://www-
stat.stanford.edu/tibs/SAM/index.html)151 as previously described 152. The cutoff point for statistical 
signiﬁcance (q-value <10%) was determined by tuning the Δ parameter on the false discovery rate 
(FDR) and controlling the q-value of the selected probes. Differentially expressed genes were also 
evaluated at the highest stringency level (median FDR 0%, 90th perc  FDR 0%). The functional 
annotation analysis on the selected lists was performed by means of DAVID 6.7 
(http://david.abcc.ncifcrf.gov/) and the ToppFun option in ToppGene Suite 
(https://toppgene.cchmc.org/) tools, using the default parameters. 
 
Statistical analysis 
All contingency analyses were performed by Fisher’s exact test. A P value <0.05 was considered 
signiﬁcant for all statistical calculations. 
For survival analyses in pPCL, patients were stratiﬁed into two groups according to the occurrence of 
mutations in DIS3. The groups identified by this approach were tested for association with progression 
free survival (PFS) or overall survival (OS) using the log-rank test and the curves estimated by Kaplan–
Meier method; P values were calculated according to the standard normal asymptotic distribution. 
Survival analysis was conducted with the km.coxph.plot function of the survcomp package in R 
software. 
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Results 
Multiple myeloma and plasma cell leukemia samples  
To estimate the frequency of DIS3 mutation in plasma cell dyscrasia, we investigated by next 
generation sequencing (NGS) a retrospective cohort of 130 cases with MM at onset and 17 at relapse 
(of whom 15 were also tested at onset). Moreover, we examined 24 patients with primary PC leukemia 
(pPCL), 12 with secondary PCL and 20 multiple myeloma cell lines (see Materials and Methods for 
patient populations). 
Pathological samples from all patients (n=187) were characterized by fluorescence in situ 
hybridization (FISH) for the presence of the main molecular alterations, namely IGH@ chromosomal 
translocations and hyperdidploidy status, del(13)(q14), del(17)(p13), 1p33 (CDKN2C) loss and 1q21.3 
(CKS1B) gain aberrations as previously described 153;154. The cut-off levels considered were 10% for 
fusion or break-apart probes and 20% for numerical abnormalities, as recommended by the European 
Myeloma Network (EMN). 
Deletion of chromosome 13q was investigated in 186 cases and showed a positive result in 63 MM and 
26 PCL patients while del(17) was analyzed in 185 patients and showed a positive result in 22 cases 
(10 MM and 12 PCL). Translocations at 14q32 involving IGH@ locus were detected in the 50% of cases 
(92/184): in particular, 15 MM and three PCL patients had t(4;14) while t(11;14), investigated in 184 
cases, was present in 33 MM and in 12 PCL. T(14;16) was analyzed in 184 patients and showed a 
positive result in 20 cases (seven MM and 13 PCL), while t(14;20), investigated in 182 samples, was 
identified in one MM and two PCL. T(6;14) was analyzed in 166 samples and showed a positive result 
in 6 samples (all MM).  Of the 172 analyzed cases, 55 MM and 3 PCL showed a hyperdiploid status 
according to FISH evaluation criteria 152. Deletions of chromosome 1p were analyzed in 163 patients 
and were identiﬁed in 22 cases (11 MM and 11 PCL), while gain in 1q region, investigated in 178 cases, 
was found in 62 MM and 20 PCL patients. Twelve cases (3 MM and 9 PCL) showed the concomitant 
presence of both aberrations. 
According to the TC classification, our MM series was stratiﬁed as follows: 28 patients in TC1, 
including 14 carrying t(11;14) and expressing high levels of CCND1 and four harboring a t(6;14) 
strongly deregulating CCND3; 25 patients in TC2, all of whom  were negative  for  IGH  translocations  
and expressing CCND1 at moderate levels than TC1, but not CCND2 or CCND3; 36 patients in TC3, all of 
whom were negative for the IGH translocation and CCND1 expression, most of whom expressed 
CCND2 at variable levels; 13 patients in TC4, all harboring t(4;14); and five patients in TC5, all carrying 
deregulated MAF or MAFB genes. The patients in TC4 and TC5 were characterized by a consistent 
expression of CCND2, with the TC5 patients generally showing the highest levels. 
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Assessment of DIS3 mutation by NGS  
To estimate the frequency of DIS3 mutation, all samples (n. 203) were subjected to deep sequencing of 
the two functional domains of the gene: the PIN domain, endowed of endonucleolytic activity, 
spanning from exon 1 to exon 4 while the RNB domain, with a exonucleolytic activity, spanning from 
exon 10 to exon 18.  
The obtained sequencing reads were mapped to the reference sequence (RefSeqGRCh37.p13) and 
analyzed by the Amplicon Variant Analyzer (AVA) software to establish the mutant allele frequency. 
DIS3 exons 1-4 and 10-18 reference sequences were extracted from hg19 Human Genome Version 
(Transcript Variant 1, NM_014953.4) together with both neighbor intronic regions. Such sequences 
were used as reference sequences to align every reads and the final alignments were checked 
manually.  
Using the AVA-Software, we combined the raw data obtained from the single sequencing runs and 
detected a total of 198 deletions, insertions and single nucleotide variations (SNVs), with an average 
and a median depth of coverage of 253x and 245x, respectively (range: 64-1160). 
To exclude germline variants, we sequenced the matched normal DNA, when available, or consulted 
the Human dbSNP Database at NCBI (Build 142) (http://www.ncbi.nlm.nih.gov/snp), and removed 
from the analysis changes present in germline samples or with a corresponding rs (reference SNP ID 
number) entry (unless the same variant was also included in NCBI ClinVar database). We found only 
one germline SNV (P635S) carried by eight patients, also reported in dbSNP (rs35017269) with a 
global Minor Allele Frequency (MAF) of 0.008/18. 
After exclusion of intronic, synonymous and germline variants, deep sequencing of DIS3 revealed 41 
different coding mutations. The presence of each non-synonymous SNV was verified in an independent 
PCR product, analyzed by conventional sequencing whenever the sensitivity of the Sanger’s method 
was consistent with the variant allele frequency, or by an additional and ultra-deep pyrosequencing 
run (median depth of coverage = 1110x) in case of variants at low allele frequency. 
The high sensitivity of the method allowed mutation detection even at a very low variant allele 
frequency. In fact, a considerable proportion of patients presented with a small mutation load. 
Among the 41 tumor-specific mutations identified, 30 (73%) were SNVs and the remaining 11 (27%) 
were indels (Table 1). At the amino acid level, 29 mutations (71%) were missense, 10 (24%) 
introduced a frameshift, and two (5%) an in-frame deletion. Nine of these variants have been already 
reported by others, eight of which also specifically in MM patients, while 32 were novel. 
DIS3 mutations globally affected 43 samples: 26 MM at diagnosis (26/130, 20%), four at relapse (4/17, 
23.5%), six primary PCL (6/24, 25%), four sPCL (4/12, 33.3%) and three multiple myeloma cell lines 
(3/20, 15%). The major molecular features of the 43 mutated cases are reported in Table 4. 
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Table 4. Summary of non-synonymous DIS3 variants identified by NGS. 
Variant (GRCh37.p13) Exon Type
‡
 Mutation AA change dbSNP ID 
COSMIC ID 
(v71) 
MM literature 
NC_000013.10:g. 73355804_73355830del 1 deletion 
IN FRAME 
DELETION 
del AA 48-
56 
/ / / 
NC_000013.10:g.73355968C>T 1 SNV IN FRAME 
DELETION 
del AA 1-16 / / / 
NC_000013.10:g.73355891T>C 1 SNV MISSENSE D27G / / / 
NC_000013.10:g.73355093T>C 2 SNV MISSENSE T93A / / / 
NC_000013.10:g.73355010G>C 2 SNV MISSENSE F120L / / / 
NC_000013.10:g.73355048G>A 2 SNV MISSENSE R108C / / 
different variant at 
the same position 
reported by Lohr
61
 
NC_000013.10:g.73355008T>G 2 SNV MISSENSE Y121S / / YES, by Keats in 
the same cell line 
NC_000013.10:g.73355018T>C 2 SNV MISSENSE K118E / / / 
NC_000013.10:g.73355110T>C 2 SNV MISSENSE N87S / / / 
NC_000013.10:g.73352393A>C 3 SNV MISSENSE V171G / / YES, by Keats in 
the same cell line 
NC_000013.10:g.73352416_73352417insT 3 insertion FRAMESHIFT M163Ifs*15 / / / 
NC_000013.10:g.73346400C>T 10 SNV MISSENSE R467Q rs201674523 / YES, by Lohr61 
NC_000013.10:g.73346338C>T 10 SNV MISSENSE D488N / COSM158635 YES, by 
Lohr
61
,Weissbach
137
 
NC_000013.10:g.73346340T>A 10 SNV MISSENSE D487V / / 
position previously 
shown to be critical for 
exoribonucleotydic 
activity of hDIS3
117
 
NC_000013.10:g.73346341C>G 10 SNV MISSENSE D487H / / 
position previously 
shown to be critical for 
exoribonucleotydic 
activity of hDIS3
117 
NC_000013.10:g.73346338del 10 deletion FRAMESHIFT D488Mfs*22 / / 
different variant at 
the same position 
reported by Lohr
61
 
NC_000013.10:g.73346340del 10 deletion FRAMESHIFT D487Afs*23 / / / 
NC_000013.10:g.73346400del 10 deletion FRAMESHIFT R467Qfs*4 / / / 
NC_000013.10:g.73345240G>A 12 SNV MISSENSE S550F / / 
different variant at 
the same position 
reported by Lohr
61
 
NC_000013.10:g.73345094T>C 13 SNV MISSENSE H568R / / / 
NC_000013.10:g.73345097T>C 13 SNV MISSENSE N567S / / / 
NC_000013.10:g. 73342930C>T 14 SNV MISSENSE E626K / / / 
NC_000013.10:g. 73342930del 14 deletion FRAMESHIFT E626Kfs*5 / / / 
NC_000013.10:g.73343049_73343050insA 14 insertion FRAMESHIFT A586Vfs*7 / / / 
NC_000013.10:g.73337707G>T 16 SNV MISSENSE A670D / / / 
NC_000013.10:g.73337683_73337684insT 16 insertion FRAMESHIFT I678Nfs*3 / / / 
NC_000013.10:g.73337692_73337693insT 16 insertion FRAMESHIFT A675Dfs*6 / / 
different variant at 
the same position 
reported by Lohr
61
 
NC_000013.10:g.73337693_73337694insT 16 insertion FRAMESHIFT A675Sfs*6 / / 
different variant at 
the same position 
reported by Lohr
61
 
NC_000013.10:g.73336112T>C 17 SNV MISSENSE H764R / / / 
NC_000013.10:g.73336078A>C 17 SNV MISSENSE F775L / / YES, by Lohr61 
NC_000013.10:g.73336064C>T 17 SNV MISSENSE R780K / COSM329311 
YES, by 
Chapman
43
, 
Walker
136
,Lohr
61
 
and Weissbach
137
 
NC_000013.10:g.73336064C>G 17 SNV MISSENSE R780T / / YES, by Lohr61 
NC_000013.10:g.73336113G>A 17 SNV MISSENSE H764Y / / / 
NC_000013.10:g.73337650C>T 17 SNV MISSENSE R689Q / / YES, by Lohr61 
NC_000013.10:g.73336077T>G 17 SNV MISSENSE T776P / / / 
NC_000013.10:g.73336064del 17 deletion FRAMESHIFT R780Kfs*25 / / 
different variant at the 
same position reported 
by Chapman
43
, 
Walker
136
, 
Lohr
61
,Weissbach
137
 
NC_000013.10:g.73336113G>C 17 SNV MISSENSE H764D / / / 
NC_000013.10:g.73335837G>A 18 SNV MISSENSE R820W rs372878316 / / 
NC_000013.10:g.73335816C>G 18 SNV MISSENSE A827P / / / 
NC_000013.10:g.73335930G>A 18 SNV MISSENSE R789W / / / 
NC_000013.10:g.73336151G>T 18 SNV MISSENSE A751D / / / 
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Mutant allele frequency ranged from 0.38% to 100% (Figure 11): 14 cases show an allele frequency 
>80% while in all the remaining cases, the percentage of variant reads was suggestive of a mutation 
present in heterozygosis or in a tumor subclone. Of the 41 variants identified in our cohort of patients, 
25 (25/41, 61%) are present at clonal level while 16 (16/41, 39%) only at low allele frequency (below 
the detection limit of Sanger, i.e. about 10%).  
 
 
Figure 11. Variant allele frequency of DIS3-mutated cases. 
 
As regards subclonal mutations, these affected only MM at onset (10/130, 7.7%) and were present 
with allele frequency comprised between 0.38 and 4.71%; seven of these mutations were SNVs while 
the remaining three were insertions causing a frameshift. Eight cases showed both clonal and 
subclonal mutations: seven subclonal mutations causes a frameshift and only one is a SNV. 
Additionally, of the 30 SNVs, all but one (a mutation affecting the ATG start codon causing a frameshit) 
were analyzed by five damage prediction databases, namely Polyphen2, Mutation Taster, Mutation 
Assessor, LRT and SIFT. These databases predict possible impact of an amino acid substitution on the 
structure and function of protein. According to all the databases, 23 SNVs were designated ‘damaging’ 
(mutations that occur at conservative sites or lead to structural changes) and three ‘benign’ while, 
among the remaining three variants, there was not overlap of predictions between the databases 
(Table 5). 
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Table 5. Results of damage predictions softwares.  
 
The great majority of mutations identified in our cohort of patients affected the RNB domain (30/41, 
73.2%), while only nine variants (22%) were present in the PIN domain. The remaining two SNVs 
were found in a region downstream of the RNB domain. Eight of these mutations were recurrent, each 
affecting two or more patients: of these, three SNVs were not described previously (T93A, R789W and 
R820W) while five targeted conserved residues (F775, D488 and R780) already reported by others 
authors 43;61;72;137.  
In agreement with Weissbach et al 137, we found two SNVs, R780K (indicated as R750K by Chapman et 
al and Walker et al) and D488N that are located in recurrent mutational hot-spots within fully 
conserved amino acid in RNB domain. This is an important finding because recurrent site-specific 
somatic SNVs in MM are rare 65. Overall, of the other mutations that occurred in the RNB domain, 11 
targeted highly conserved amino acids. Particularly, one of the most frequent mutation affected 
conserved amino acid R780, and was carried by five patients (two MM and three PCL): this mutation 
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affected an amino acid residue involved in substrate binding and cause a strong reduction of the 
exonucleolytic activity 68. Similar effects were caused by the D487 substitution (two mutated MMs) 68. 
D488 was another of the most frequently mutated residue in our patients’ cohort (four cases carrying 
a mutation in its specific codon: three MMs and one PCL, respectively). These variations affected an 
aspartic acid residue involved in substrate catalysis essential for magnesium ion coordination in the 
catalytic centre of the protein. It could be possible that a DIS3 mutation at position D488, which lies 
next to D487, might have a similar effect to those displayed by D487 variants. Otherwise, the 
mutations in the PIN domain did not target particularly conserved amino acid residues, predicted to 
coordinate an efficient degradation/processing of several natural exosome substrates.  
Interestingly, inactivating variants that affected conserved amino acid residues R780, D488 and D487, 
were always detected (both in disomic both in 13q deleted patients) with an allele frequency lower 
than 50% in our dataset (and in according to Weissbach et al 137 and Lohr et al 61, suggesting that the 
exclusive expression of such DIS3 proteins  may have harmful effects on cell.    
Furthermore, one sample (PCL-042) displayed more than one mutation in the RNB domain at high 
allelic frequency (R780K and E626K in 45.95% and 33.15% of mutated sequencing reads, 
respectively), while a MM patient harbored a 9aa in-frame deletion in the PIN domain 
(Ala47_Pro55del) and a missense substitution in the RNB domain (A751D). Additionally, these 
samples displayed, in addition to high frequency mutations, also low-level mutations. 
Finally, only three (KMS26, KMS 27 and OPM2) out of the 21 HMCLs tested showed DIS3 mutations; in 
agreement with Weissbach et al 137, also we founded the same SNV (Y121S) in the OPM2 cell line. 
 
FISH analysis 
The results of the FISH analysis of our mutated cases are reported in Table 6.  Among the mutated 
patients (n=40), we observed deletion of chromosome 13 in 22 patients (22/40, 55%), whereas 
del(17)(p13) was found in three cases (7.5%). Translocations at 14q32 involving IGH@ locus were 
detected in the large majority of cases (28/40, 70%); in particular, t(4;14) was present in six patients 
(15%) while t(11;14) and t(14;16), each investigated in 38 cases, were present in 15 (39.5%) and in 
five (13.2%) patients respectively. The t(6;14) was analyzed in 35 cases, all but one found to be 
negative for this lesion. The t(14;20) was investigated in 36 cases and showed a positive result in one 
case (2.8%). Deletions of chromosome 1p were analyzed in 35 patients and were identiﬁed in 3 cases 
(8.6%), while gain in 1q region, investigated in 37 cases, was found in 20 (54.1%) patients. Only one 
case (PCL-019) showed the concomitant presence of 1q gain and 1p loss. Finally, of the 35 analyzed 
cases, five showed a hyperdiploid status.  
  
 Table 6.Clinical and molecular characteristics of 40 MM/PCL patients and three HMCLs carrying non-synonymous DIS3 mutations. 
Sample name 
Disease 
stage‡ 
Variant (GRCh37.p10) 
% of mutated 
sequencing 
reads 
AA change del(13) del(17p) 1q gain 1p loss t(4;14) t(11;14) t(14;16) t(14;20) t(6;14) HD 
MM-004_2 MM, R NC_000013.10:g.73335816C>G 97.12% A827P - - + - - - + - - - 
MM-034 MM, E NC_000013.10:g.73337692_73337693insT 0.44% A675Dfs*6 - - - - - - - - - + 
MM-036 MM, E NC_000013.10:g.73336078A>C 92.57% F775L + - + nd - - - - - - 
MM-042 MM, E NC_000013.10:g.73346338C>T 4.57% D488N + - + - + - - - - + 
MM-055 MM, E NC_000013.10:g.73343049_73343050insA 0.83% A586Vfs*7 - - - nd - + - - - - 
MM-123 MM, E NC_000013.10:g.73355010G>C 95.30% F120L + - + - + - - - - - 
MM-143_1 MM, E NC_000013.10:g.73355891T>C 0.62% D27G - - + - - - - - - + 
MM-150 MM, E NC_000013.10:g.73345097T>C 0.51% N567S - - + - - - - - - + 
MM-207 MM, E 
NC_000013.10:g.73336113G>A 
NC_000013.10:g.73335837G>A 
NC_000013.10:g.73336113G>C 
NC_000013.10:g.73336077T>G 
24.58% 
2.05% 
1.95% 
0.79% 
 
H764Y 
R820W 
H764D 
T776P 
 
+ - + - - - - - + - 
MM-208 MM, E NC_000013.10:g.73352416_73352417insT 0.38% M163Ifs*15 - - - - + - - - - - 
MM-213 MM, E NC_000013.10:g.73355093T>C 56.57% T93A + - - - - + - - - - 
MM-263_1 MM, E 
NC_000013.10:g.73346400C>T 
NC_000013.10:g.73346400del 
31.14% 
5.93% 
R467Q 
R467Qfs*4 
+ - + - + - - - - - 
MM-263_2 MM, R NC_000013.10:g.73346400C>T 81.90% R467Q + - + - + - - - - - 
MM-279 MM, E NC_000013.10:g.73355110T>C 2.93% N87S + - + - - - - nd nd nd 
MM-281_1 MM, E NC_000013.10:g.73336064C>T 36.80% R780K - - - - - - - - - - 
MM-310 MM, E NC_000013.10:g.73345094T>C 0.50% H568R - - - - - + - - - - 
MM-335 MM, E NC_000013.10:g.73335930G>A 94.20% R789W + - - - - - + - - - 
MM-340_1 MM, E 
NC_000013.10:g.73355804_73355830del 
NC_000013.10:g.73336151G>T 
NC_000013.10:g.73337650C>T 
54.86% 
45.71% 
2.2% 
del AA 48-56 
A751D 
R689Q 
+ - - - - + - - - - 
MM-340_2 MM, R 
NC_000013.10:g.73355804_73355830del 
NC_000013.10:g.73336151G>T 
61% 
47.27% 
del AA 48-56 
A751D 
+ - - - - + - - - - 
MM-343 MM, E NC_000013.10:g.73346338C>T 
46.18% 
5.96% 
D488N 
D488Mfs*22 
- - - - - + - - - - 
MM-372_1 MM, E NC_000013.10:g.73346341C>G 35.48% D487H - - + - - + - - - - 
MM-372_3 MM, CPT NC_000013.10:g.73346341C>G 10% D487H + - + - - + - - - - 
MM-381 MM, E NC_000013.10:g.73336064C>G 16.38% R780T - - - - - - - nd nd nd 
MM-386 MM, E NC_000013.10:g.73345240G>A 35.11% S550F - - nd nd - nd nd nd nd nd 
MM-398 MM, E NC_000013.10:g.73346338C>T 3.85% D488N + - + - - + - - - - 
MM-414 MM, E NC_000013.10:g.73336078A>C 4.71% F775L - - - - - + - - - - 
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Sample name 
Disease 
stage‡ 
Variant (GRCh37.p10) 
% of mutated 
sequencing 
reads 
AA change del(13) del(17p) 1q gain 1p loss t(4;14) t(11;14) t(14;16) t(14;20) t(6;14) HD 
MM-424 MM, E NC_000013.10:g.73355048G>A 94.33% R108C + - - + - - - - - + 
MM-445 MM, E NC_000013.10:g.73335837G>A 98.36% R820W + - + - - + - - nd - 
MM-464 MM, E NC_000013.10:g.73355968C>T 50.99% del AA 1-16 + - + - - - - - - - 
sMM-317 MM, E 
NC_000013.10:g.73346340T>A 
NC_000013.10:g.73346340del 
40.3% 
3.32% 
D487V 
D487Afs*23 
- - + - - + - - - - 
PCL-001 pPCL, E NC_000013.10:g.73337707G>T 97% A670D + - nd nd - - - + - nd 
PCL-015 pPCL, E NC_000013.10:g.73355018T>C 90.05% K118E + - + - - - + - - - 
PCL-019 pPCL, E 
NC_000013.10:g.73336064C>T 
NC_000013.10:g.73336064del 
47.75% 
0.78% 
R780K 
R780Kfs*25 
+ + + + - - + - - - 
PCL-021 pPCL, E NC_000013.10:g.73355093T>C 100% T93A + - + - + - - - - - 
PCL-035 pPCL, E NC_000013.10:g.73336064C>G 45.04% R780T - - - - - + - - - - 
PCL-036 pPCL, E NC_000013.10:g.73336112T>C 97.59% H764R + - - - - + - - - - 
MM-281_2 sPCL NC_000013.10:g.73336064C>T 47.56% R780K - + - + - - - - - - 
PCL-011 sPCL NC_000013.10:g.73335930G>A 91.1% R789W + + + - - - + - - - 
PCL-041 sPCL 
NC_000013.10:g.73346338C>T 
NC_000013.10:g.73346338del 
45.68% 
6.4% 
D488N 
D488Mfs*22 
- - nd nd - nd nd nd nd nd 
PCL-042 sPCL 
NC_000013.10:g.73336064C>T 
NC_000013.10:g.73342930C>T 
NC_000013.10:g.73342930del 
45.95% 
33.15% 
3.42% 
R780K 
E626K 
E626Kfs*5 
- - - - - + - - - - 
KMS26 HMCL NC_000013.10:g.73352393A>C 100% V171G nd nd nd nd + - + - nd nd 
KMS27 HMCL 
NC_000013.10:g.73346338C>T 
NC_000013.10:g.73346338del 
49.68% 
6.92% 
D488N 
D488Mfs*22 
nd nd nd nd nd nd nd nd nd nd 
OPM2 HMCL 
NC_000013.10:g.73355008T>G 
NC_000013.10:g.73337683_73337684insT 
NC_000013.10:g.73337693_73337694insT 
91.79% 
0.73% 
0.73% 
Y121S 
I678Nfs*3 
A675Sfs*6 
nd nd nd nd + - - + nd nd 
  
As regard the association of DIS3 mutations and chromosomal aberrations, we observed a positive 
association with the occurrence of translocations involving IGH@ locus, particularly with the t(11;14) 
(Fisher’s exact test P=0.0208) (Figure 12A), and a negative association with hyperdiploid cases 
(Fisher’s exact test P  =0.0086) (Figure 12B), but none association with 13q and 17p deletion, gain of 
chromosome 1q and loss of chromosome 1p.  
 
 
 
Figure 12. Pie chart of the proportional representation of IGH-translocation (A) and hyperdiploidy (HD) (B) in 
whole patients’ cohort  and DIS3-mutated cases.  
 
Among our mutated cases with 13q deletion, mutant allele frequency was ≥90% in 10 out of 22 
patients (5 MM and 5 PCL) while, in the remaining 12 patients (11 MM and 1 PCL), the percentage of 
variant reads was comprise between 3 and 82%. In the remaining 18 cases, disomic for chromosome 
13, the percentage of variant reads of all but one samples (one relapsed MM patient harboring a 
mutation presumably present in both alleles at a frequency of  97.2%) was suggestive of a mutation 
present in heterozygosis or in a small tumor subclone (range between 0.38-47.56%). 
 
Sequential analysis of DIS3 mutations  
To gain further insight into the state of DIS3 mutation longitudinally, we analyzed samples of 20 
patients for whom bone marrow specimens were collected at two different time points: in particular, 
fifteen MM and two pPCL cases at onset and at relapse, respectively; two patients with MM at onset 
and at leukemic transformation, and one patient in early and relapsed leukemic phase of MM (Figure 
13).  
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Figure 13. Grafic representation of DIS3 mutations during disease progression. 
 
Fifteen cases displayed a wild-type status for the gene at both time-points, while one patient that 
harbored the R780K variant showed a quite constant load during disease course (present in 36.8% of 
sequencing reads of sample obtained at diagnosis and in 47.56% during leukemic transformation). 
One wild type MM sample at onset acquired a SNV (A827P) detected in 97.1% of the sequencing reads 
at relapse: this patient showed two copies of chromosome 13 both at onset both at relapse, and also 
the other cytogenetic lesions remained stable during disease progression. A considerable increase in 
mutation burden was observed in only one MM case, with R467Q mutation occurring in 31.1% of the 
sequencing reads obtained at onset and 81.9% in the sample obtained at relapse. Additionally, this 
case carried a frameshift mutation at the same position at diagnosis that disappeared at relapse. The 
case MM-372 harbored the D487H variant at onset but showed a decrease in mutation burden during 
tumor progression (with an allele frequency of 35.48% at MM onset and 10% at post-therapy control). 
One case carried at onset three variants (del AA48-56, A751D and R689Q at 54.86%, 45.71% and 
2.20% respectively) but at relapse only two (del AA48-56 and A751D) remained stable (with an allele 
frequency of 61% and 47.27% respectively) and the R689Q disappeared. The disappearance of a high 
frequency mutation was never observed in our cohort. 
 
Expression of DIS3 variants on cDNA 
To verify if the mutations detected on genomic DNA are also expressed at transcriptomic level, we 
performed deep sequencing of cDNA of the DIS3-mutated cases. In particular, compatibly with the 
availability of material, 23 DIS3 variants were evaluated. NGS results indicated that mutant allele 
frequencies detected on genomic DNA and on retrotranscribed total RNA are linearly correlated 
(Figure 14, showing the respective frequencies lying on the leading diagonal of the plot); in particular, 
a good level of correlation was found for all clonal variants, that were confirmed on cDNA generally at 
quite comparable allele frequency, while all but one subclonal mutations were not detectable at 
transcriptomic level (Figure 15). 
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Figure 14. Mutant allele frequency of mutations observed on the cDNA (y-axis) plotted against mutant allele 
frequency observed on the genomic DNA (x-axis).   
 
 
Figure 15. Variant allele frequencies indentified on genomic DNA and on cDNA. 
 
Transcriptomic profile of DIS3-mutated patients 
To identify transcriptomic profiles possibly related to DIS3 mutations identified by NGS in MM 
patients, gene expression profiling was performed in a large part (n=102) of the samples analyzed by 
sequencing, including wild-type cases for the gene (n=89) and patients carrying mutations in DIS3 
(n=13), arbitrarily establishing 20% as the lower variant allele frequency cut-off, assuming that 
alterations present in a very limited number of MM cells might not appreciably affect gene expression. 
Supervised analysis revealed 119 genes differentially expressed between DIS3 mutated and DIS3 wild-
type cases; all this genes were up-regulated in DIS3 mutated patients and 19 of these genes emerged at 
the highest stringency level. Notably, only seven of the 19 differentially expressed genes at the highest 
stringency level were protein coding, while ten genes encode for ncRNA, of which five were long non-
coding RNAs and the others were not characterized; among protein coding genes, it is worth noting 
APOBEC4, belonging to a gene family involved in mRNA editing, somatic hypermutation and 
recombination of immunoglobulin genes.  
Interestingly, functional enrichment analysis revealed the involvement of a statistically significant 
fraction of modulated transcripts in single-stranded RNA binding at molecular function level 
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(GO:0003727, q-value=1.96E-02), defense response to virus at biological process level (GO:0000165, 
q-value=1.96E-02) and interferon alpha/beta signaling at pathway level (187104BioSystems: 
REACTOME, q-value=8.23E-03). 
 
Prognostic impact of DIS3 mutations in pPCLs. 
In the 16pPCL patients for whom the follow-up was available, the association of DIS3 mutations with 
clinical outcome was tested, comparing wild-type patients (n=12) with those characterized by 
mutations in PIN or RNB functional domains of DIS3 (n=4). Mutational events did not show any impact 
neither on PFS nor OS (Figure 16). Likewise, the response rate after a 4-cycle therapy with low-dose 
lenalidomide-dexamethasone (assessed according to International Uniform Criteria 155;156 and 
representing the primary endpoint of the RV-PCL-PI-350trial) did not associate with the occurrence of 
DIS3 mutations (Fisher’s exact test). 
 
 
Figure 16. Correlation of genetic events with clinical outcome. Overall survival (A) 
and progression-free survival (B) of patients with DIS3 WT compared with DIS3 
mut according to a univariate analysis. 
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Discussion 
DIS3 is an active part of the human exosome complex that possesses both exo- and endonucleolytic 
activity and it is involved in regulating the processing and abundance of all RNA species 117. Recently, 
the DIS3 gene has emerged as recurrently mutated in MM patients from initial whole-genome and 
exome sequencing studies 43;61;65;136;137). To characterized further the molecular spectrum of DIS3 
mutations in MMs, PCLs and HMCLs samples, we performed deep amplicon sequencing that covered 
the PIN (exons 1-4) and the RNB (exons 10-18) DIS3 functional domains.  
To the best of our knowledge, this is the first study assessing DIS3 mutational status by means of next 
generation sequencing (NGS) technology in a large cohort of patients at different stages of plasma cell 
dyscrasia, evaluating it in the context of other clinical and biological features of the disease and 
determining a DIS3 mutation-associated transcriptional signature in MM. 
In our cohort of patients, DIS3 mutations globally affect 26 MM at diagnosis (26/130, 20%), four at 
relapse (4/17, 23.5%)(of whom three mutated also at onset), six primary PCL (6/24, 25%), four 
secondary PCL (4/12, 33.3%) and three multiple myeloma cell lines (3/20, 15%).  
The frequency of DIS3 mutations in MM at onset is similar to that reported by Walker et al 136 that 
analyzed a cohort of patients exclusively composed by IGH-translocated samples. However, it is higher 
than that obtained in unselected patients’ cohorts through less sensitive approaches by Chapman et al 
43, Lohr et al 61 and Bolli et al 20, who reported a percentage of mutated MM samples of 10.5%, 11% and 
<3%, respectively. More recently Weissbach et al 137, despite yielding a high sequencing coverage 
comparable to that obtained by us, reported a mutation frequency of 11%. 
Interestingly, the occurrence of DIS3 mutations increased (although not at statistically significant 
level) in primary and secondary PCLs (25% and 33.3%, respectively), confirming the evidence that the 
complexity of genome aberrations increases with disease stage136. DIS3 mutation status has never 
been thoroughly investigated before in these aggressive forms of plasma cell dyscrasia, and it would 
be worthy to confirm these findings  in larger patients’ cohorts, although difficult to collect due to the 
rarity especially of primary forms.  
In line with what reported by Chapman et al 43, but in contrast with Weissbach et al 137, we found an 
accumulation of DIS3 mutations in the RNB domain (30/41, 73.2%), while only nine variants (22%) 
were present in the PIN domain. The remaining two SNVs were found in a region downstream of the 
RNB domain. Interestingly, in our cohort of patients the majority of SNVs detected in RNB domain 
were located in highly conserved residues, suggesting their potential impact on the exonucleolytic 
activity of the enzyme68. Among these, one of the most frequently mutated residue was the conserved 
amino acid R780 and found altered in five patients of current dataset and in six patients of previously 
published reports (one by Chapman et al 43; three by Lohr et al, 61; one by Walker et al 136, and one 
Waissbach et al 137). It is involved in substrate binding, and its mutation has been reported in yeast and 
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bacteria to cause a strong reduction of the exonucleolytic activity leading to a decreased degradation 
rate of RNA molecules belonging to different RNA classes68. Similar effects were caused by the D487 
substitution 68;157, reported for the first time in our cohort and affecting two MM patients. D488 was 
another of the most frequently mutated residue: in our patients cohort four cases carried a mutation in 
this amino acid (three MMs and one PCL), while Lohr et al 61and Weissbach et al 137found this residue 
mutated in two and one patients, respectively. D488 is an aspartic acid residue involved in substrate 
catalysis essential for magnesium ion coordination in the catalytic centre of the protein and, because it 
lies next to D487, its substitution might have a similar effect to that displayed by D487 variants. 
Interestingly, these inactivating variants that affected conserved amino acids R780, D488 and D487 
were always detected at allele frequency lower than 50% in our cohort of patients (in agreement with 
what found in the series of Weissbach et al 137 and Lohr et al 61, suggesting the hypothesis that the 
exclusive expression of such DIS3 mutants in the absence of DIS3 wild type protein might have 
deleterious cellular effects. Finally, two of these recurrently mutated amino acid  residues in our 
dataset, i.e. D488 and R780, were recently proposed as mutational hot-spots by Weissbach et al 
137.This is an important finding, because recurrent site-specific somatic SNVs in MM are rare 65.  
As regard specific amino acid substitution, seven mutations of this dataset are recurrent, affecting two 
or more patients: of these, three SNVs were not described previously (T93A, R789W and R820W) 
while four (F775L, D488N, R780K and R780T ) were already reported by other authors 43;61;136;137. 
Notably, one MM sample of our dataset harbored a 9aa in-frame deletion in the PIN domain 
(Ala47_Pro55del) and a missense substitution in the RNB domain (A751D). In the yeast system, 
Tomecki et al 68 showed that MM-associated mutations in hDIS3 RNB domain that inhibit its 
exonuclease activity are indeed synthetically lethal with inactivation of hDIS3 endonucleolytic activity, 
suggesting that the PIN domain may be also a potential drug target for cancers bearing DIS3 mutations.  
With regard to the correlation of DIS3 variants with cytogenetic alterations, in agreement with 
previous findings 43, 61, 136;137.) we observed a positive association between DIS3 mutations and the 
occurrence of translocations involving IGH@ locus (particularly with the t(11;14)). With this regard it 
has been suggested that alteration of exosome complex (known to be involved in AID-mediated 
immunoglobulin hypermutations and class switches) due to DIS3 mutations, may lead to chromosomal 
translocations 133. 
Moreover, we showed a negative association between DIS3 mutated cases and hyperdiploidy, but no 
association with 13q (in contrast to previous findings of Chapman et al 43, Lohr et al 61, Walker et al 136 
and Weissbach et al 137) and 17p deletion, gain of chromosome 1q and loss of chromosome 1p.  
In a considerable fraction of patients, DIS3 variants were identified at allele frequencies suggestive of 
the occurrence of the mutations in minor tumor subclones, confirming recently published data137. 
Besides a fraction of cases positive for del(13) and carrying mutations at allele frequency around 
100%, and disomic patients with about 50% of mutated sequencing reads, we indeed detected DIS3 
substitutions at variant allele frequencies supporting the previously described and validated subclone 
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theory 20;27;136. Notably, mutations at the lowest allele frequencies (undetectable by Sanger) exclusively 
affected MM patients at onset. Recently, Weissbach et al 137 reported that patients with DIS3 mutations 
in a minor subclone showed a worse prognosis if compared with patients with mutations in a major 
subclone; unfortunately, we could not confirm this finding due to the unavailability of the clinical data 
for mutated patients at subclonal level. 
Samples with DIS3 mutations can also have deletion of 13q, including the DIS3 locus in MM, and so 
deletion and mutation of DIS3 may be collaborating lesions. The gene of interest at 13q14 has been 
debated for many years, and it remains unclear which region(s) of chromosome 13 is pathologically 
relevant; the discovery of another altered gene in this region will confound the situation further and 
only through analyses of large datasets, comprising copy number and mutational data, will the true 
nature of these abnormalities be discovered.  
Although a number of studies have interrogated the role of mutational changes in cancer and in 
myeloma, the phenotypic impact of mutations has not been evaluated for the majority of these 
alterations 158. The ultimate signiﬁcance of these genetic changes will depend on whether the mutated 
allele is expressed, and whether the mutation affects expression, splicing, or function of the gene 
product. Recently, Rashid et al 159,for the first time in MM, used RNA-seq to examine the relationship 
between mutational status of a gene and its allelic expression, revealing that the majority of mutations 
are found in genes that have low or no detectable biological expression. Additionally, mutated genes 
often show differential allelic expression in multiple myeloma patient samples. In our study, we 
sequenced cDNA of the DIS3-mutated cases to verify if the mutations detected on genomic DNA are 
also expressed at transcriptomic level. In contrast with Rashid et al 159, we were able to confirm all 
clonal variants on cDNA, generally at quite comparable allele frequency, suggesting that these 
mutations may be functionally relevant. Furthermore, confirming the cellular expression of DIS3 
mutant proteins, our gene expression profiling analysis revealed 119 differentially expressed genes 
(all up-regulated in mutated cases) between DIS3 mutated and DIS3 wild-type cases. Functional 
enrichment analysis revealed the involvement of a statistically significant fraction of modulated 
transcripts in single-stranded RNA binding at molecular function level, consistent with the finding 
reported by Tomecki et al 68 that MM-associated DIS3 mutations cause perturbations in cellular RNA 
metabolism. Furthermore, these data, although requiring confirmation in independent patients’ series, 
support the hypothesis that the role of DIS3 mutations in cancer development could be mediated by 
the alteration of gene expression, that could be a direct effect or a consequence of the overabundance 
(resulting from DIS3 dysfunction and actually detected in our mutated samples) of unstable non-
coding transcripts affecting chromatin structure and thus the expression of genes important for 
carcinogenesis 68. 
Furthermore, looking at DIS3 mutations during disease progression in serially analyzed patients, we 
observed a similar scenario to that found by Bolli et al 20, who exclusively reported clonal variants at 
both time points or acquired/increased variants in the late sample, consistent with the expected 
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positive selection of mutated subclones; only one MM case of the present series showed a decrease in 
mutation burden during tumor progression (with an allele frequency of 35.48% at MM onset and 10% 
at post-therapy control), and the disappearance of a high frequency mutation was never observed in 
our cohort. 
The finding that the identified DIS3 mutations did not have clinical impact was consistent with what 
reported by Weissbach et al 137, who found a trend towards a lower median overall survival (OS) but 
no effect on event-free survival (EFS) in patients with mutations in DIS3 compared with those without. 
Moreover, no differences in response to therapy were observed 137. In our study, we tested the 
association of DIS3 mutations with clinical outcome in 16 pPCL patients for whom the follow-up was 
available. In agreement with Weissbach et al 137, mutational events did not show any impact neither on 
PFS nor OS. Likewise, the response rate after a 4-cycle therapy did not associate with the occurrence of 
DIS3 mutations. 
These ﬁndings, however, have to be treated with caution as, despite the robust size of the study cohort, 
the actual number of patients with DIS3 mutations is quite small. Thus, clearly larger, multicentre 
efforts are required to better understand the oncogenic and clinical implications of DIS3 mutations in 
MM. 
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